Citations

Citations to this article as recorded by  

• Effect of varenicline on major adverse liver outcomes in alcohol‐associated liver disease: An exploratory analysis
  Pojsakorn Danpanichkul, Yanfang Pang, Donghee Kim, Thanathip Suenghataiphorn, Donghyun Ko, Andrew F. Ibrahim, Vitchapong Prasitsumrit, Kwanjit Duangsonk, Mazen Noureddin, Karn Wijarnpreecha, Suthat Liangpunsakul
  Alcohol, Clinical and Experimental Research.2025; 49(11): 2451.     CrossRef

Citations

Citations to this article as recorded by  

• Rising drug overdose deaths in chronic liver disease in the United States, 2015–2023
  Donghee Kim, Brittany B Dennis, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
  Clinical and Molecular Hepatology.2025; 31(3): e277.     CrossRef
• Advancing Policy and Practice in Alcohol-Associated Liver Disease and Alcohol-Attributable Cancer: Correspondence to the editorial on “Rising Burden of Alcohol-Associated Liver Disease and Cancers: Insights into Sex Disparities and Policy Implications”
  Pojsakorn Danpanichkul, Donghee Kim, Karn Wijarnpreecha, Amit G. Singal, Ju Dong Yang
  Clinical and Molecular Hepatology.2025;[Epub]     CrossRef
• Extrahepatic manifestation of metabolic dysfunction-associated steatotic liver disease
  Anoushka Shenoy, Aijaz Ahmed, Donghee Kim
  Metabolism and Target Organ Damage.2025;[Epub]     CrossRef

Citations

Citations to this article as recorded by  

• Rising burden of steatotic liver disease in women of childbearing age and projections to 2035
  Youxin Wang, Ruiqiu Chen, Shi Yan Lee, Eunice X.X. Tan, Mark Muthiah, Zhou Yu, Margaret L.P. Teng, Jazleen Leo, Cheng Han Ng, Ashok Choudhury, Daniel Q. Huang
  JHEP Reports.2026; 8(1): 101646.     CrossRef
• MetALD: new insights and unraveling therapeutic potential
  Yue Feng, PanShiLi Han, Tao Liu, YanHang Gao
  Metabolism and Target Organ Damage.2025;[Epub]     CrossRef
• Sex Disparity in Major Adverse Liver Outcome and Major Adverse Cardiac Event in Alcohol‐Associated Liver Disease
  Pojsakorn Danpanichkul, Donghee Kim, Karn Wijarnpreecha, Mark D. Muthiah, Suthat Liangpunsakul
  Liver International.2025;[Epub]     CrossRef
• Advancing Policy and Practice in Alcohol-Associated Liver Disease and Alcohol-Attributable Cancer: Correspondence to the editorial on “Rising Burden of Alcohol-Associated Liver Disease and Cancers: Insights into Sex Disparities and Policy Implications”
  Pojsakorn Danpanichkul, Donghee Kim, Karn Wijarnpreecha, Amit G. Singal, Ju Dong Yang
  Clinical and Molecular Hepatology.2025;[Epub]     CrossRef
• Effect of varenicline on major adverse liver outcomes in alcohol‐associated liver disease: An exploratory analysis
  Pojsakorn Danpanichkul, Yanfang Pang, Donghee Kim, Thanathip Suenghataiphorn, Donghyun Ko, Andrew F. Ibrahim, Vitchapong Prasitsumrit, Kwanjit Duangsonk, Mazen Noureddin, Karn Wijarnpreecha, Suthat Liangpunsakul
  Alcohol, Clinical and Experimental Research.2025; 49(11): 2451.     CrossRef
• Consumo de alcohol y cirrosis en mujeres: un riesgo subestimado
  P. Huerta, J.P. Arab, L.A. Díaz
  Revista de Gastroenterología de México.2025; 90(4): 509.     CrossRef
• Alcohol use and cirrhosis in women: An underestimated risk
  P. Huerta, J.P. Arab, L.A. Díaz
  Revista de Gastroenterología de México (English Edition).2025; 90(4): 509.     CrossRef

Citations

Citations to this article as recorded by  

• Reply to correspondence on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023”
  Jeayeon Park, Su Jong Yu
  Clinical and Molecular Hepatology.2025; 31(2): e221.     CrossRef
• Neonatal liver-derived FTH1-enriched extracellular vesicles attenuate ferroptosis and ameliorate MASLD pathogenesis
  Xin Zeng, Wei Jiang, Tian Wu, Lan Li, Fudong Fu, Han Yao, Dongbo Wu
  Free Radical Biology and Medicine.2025; 240: 693.     CrossRef
• Liver-Related COVID-19 Consequences: Dynamics of Liver Health in 2.5 Years
  Ieva Vanaga, Oksana Kolesova, Aleksandrs Kolesovs, Maija Radzina, Davis Simanis Putrins, Jelena Egle, Sniedze Laivacuma, Jelena Storozenko, Ludmila Viksna
  Journal of Clinical Medicine.2025; 14(21): 7604.     CrossRef

Citations

Citations to this article as recorded by  

• Association of gut microbiota dietary index with metabolic dysfunction-associated steatotic liver disease: the mediating roles of inflammation and body mass index
  Yu Pu, Zongbiao Tan, Yanrui Wu, Suqi Zeng, Haodong He, Jixiang Zhang, Weiguo Dong
  Frontiers in Nutrition.2025;[Epub]     CrossRef
• Advances in identifying risk factors of metabolic dysfunction-associated alcohol-related liver disease
  Rui-Qi Ye, Yi-Fan Chen, Chang Ma, Xi Cheng, Wei Guo, Sha Li
  Biomedicine & Pharmacotherapy.2025; 188: 118191.     CrossRef
• Disproportionately rising mortality rates of alcohol-associated acute Pancreatitis: Analysis from centers for Disease Control and prevention database (2011–2020)
  Pojsakorn Danpanichkul, Yanfang Pang, Donghee Kim, Thanida Auttapracha, Shu-Yen Chan, Do Han Kim, Thanawin Pramotedham, Kanita Mankan, Chanokporn Puchongmart, Juan Pablo Arab, Luis Antonio Diaz, Jorge D. Machicado, Michael B. Wallace, Karn Wijarnpreecha
  Pancreatology.2025; 25(4): 508.     CrossRef
• A Comparison of the Predictive Value of 12 Body Composition Markers for Metabolic Dysfunction-Associated Steatotic Liver Disease, At-Risk Metabolic Dysfunction-Associated Steatohepatitis, and Increased Liver Stiffness in a General Population Setting
  Laurens A. van Kleef, Maurice Michel, Mesut Savas, Jesse Pustjens, Roel van de Laar, Edith Koehler, Elisabeth F.C. van Rossum, Harry L.A. Janssen, Jörn M. Schattenberg, Willem P. Brouwer
  American Journal of Gastroenterology.2025;[Epub]     CrossRef
• Extrahepatic manifestation of metabolic dysfunction-associated steatotic liver disease
  Anoushka Shenoy, Aijaz Ahmed, Donghee Kim
  Metabolism and Target Organ Damage.2025;[Epub]     CrossRef
• Organokine-Mediated Crosstalk: A Systems Biology Perspective on the Pathogenesis of MASLD—A Narrative Review
  Sandra Maria Barbalho, Lucas Fornari Laurindo, Vitor Engracia Valenti, Nahum Méndez-Sánchez, Mariana M. Ramírez-Mejía, Ricardo de Alvares Goulart
  International Journal of Molecular Sciences.2025; 26(23): 11547.     CrossRef
• Editorial: Understanding How Social Determinants of Health Impact Mortality in MASLD—Insights From a National Analysis. Authors' Reply
  Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Rohit Loomba, Aijaz Ahmed
  Alimentary Pharmacology & Therapeutics.2025;[Epub]     CrossRef

Citations

Citations to this article as recorded by  

• Diagnostic Performance of Ultrasound-Derived Fat Fraction and Automated Point Shear Wave Elastography for Hepatic Steatosis and Fibrosis in Suspected Steatotic Liver Disease: A Prospective Multicenter Study
  Jing Liang, Xueqi Li, Guangwen Cheng, Huixiong Xu, Yuli Zhu, Zhe Ma, Dong Jiang, Hao Han, Lin Chen, Liyun Xue, Xiaohui Qiao, Hong Ding
  Ultrasound in Medicine & Biology.2026; 52(1): 227.     CrossRef
• Current Burden of Lean Metabolic Dysfunction‐Associated Steatotic Liver Disease Among US Adults, 2017–2023
  Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed
  Alimentary Pharmacology & Therapeutics.2025; 61(5): 891.     CrossRef
• Editorial: Steatotic Liver Diseases Emerge as Rapidly Growing Drivers of Primary Liver Cancer in the United States—Author's Reply
  Pojsakorn Danpanichkul, Donghee Kim, Chun Wei Pan, Amit G. Singal, Ju Dong Yang, Karn Wijarnpreecha
  Alimentary Pharmacology & Therapeutics.2025; 61(6): 1059.     CrossRef
• Cigarette Smoke Contributes to the Progression of MASLD: From the Molecular Mechanisms to Therapy
  Jiatong Xu, Yifan Li, Zixuan Feng, Hongping Chen
  Cells.2025; 14(3): 221.     CrossRef
• Post-COVID-19 Pandemic Sequelae in Liver Diseases
  Cristina Stasi
  Life.2025; 15(3): 403.     CrossRef
• Alcohol–Related Liver Disease, Followed by Metabolic Dysfunction–Associated Steatotic Liver Disease, Emerges as the Fastest‐Growing Aetiologies for Primary Liver Cancer in the United States
  Pojsakorn Danpanichkul, Kwanjit Duangsonk, Markos Kalligeros, Michael B. Fallon, Chawinthorn Vuthithammee, Chun Wei Pan, Preenapun Saokhieo, William Derrick, Yanfang Pang, Vincent L. Chen, Donghee Kim, Amit G. Singal, Ju Dong Yang, Karn Wijarnpreecha
  Alimentary Pharmacology & Therapeutics.2025; 61(6): 959.     CrossRef
• Association of High‐Sensitivity Troponins in Metabolic Dysfunction‐Associated Steatotic Liver Disease With All‐Cause and Cause‐Specific Mortality
  Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
  Alimentary Pharmacology & Therapeutics.2025; 61(11): 1785.     CrossRef
• Revealing the importance of a multidisciplinary approach to reducing the global burden of SLD through the COVID-19 pandemic: Editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023”
  Jeayeon Park, Su Jong Yu
  Clinical and Molecular Hepatology.2025; 31(2): 625.     CrossRef
• The burden of steatotic liver disease before and during the COVID-19 pandemic: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023”
  Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed
  Clinical and Molecular Hepatology.2025; 31(2): e183.     CrossRef
• Reply to correspondence on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023”
  Jeayeon Park, Su Jong Yu
  Clinical and Molecular Hepatology.2025; 31(2): e221.     CrossRef
• Vibration-controlled transient elastography in shaping the epidemiology and management of steatotic liver disease: Editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023”
  Xiao-Dong Zhou, Terry Cheuk-Fung Yip, Daniel Q Huang, Mark Dhinesh Muthiah, Mazen Noureddin, Ming-Hua Zheng
  Clinical and Molecular Hepatology.2025; 31(2): 620.     CrossRef
• Addressing the burden of steatotic liver disease: The role of transient elastography: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023”
  Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed
  Clinical and Molecular Hepatology.2025; 31(2): e180.     CrossRef
• Correspondence to editorial on “Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000-2021”
  Pojsakorn Danpanichkul, Luis Antonio Diaz, Kanokphong Suparan, Karn Wijarnpreecha, Juan Pablo Arab
  Clinical and Molecular Hepatology.2025; 31(2): e200.     CrossRef
• Advances in identifying risk factors of metabolic dysfunction-associated alcohol-related liver disease
  Rui-Qi Ye, Yi-Fan Chen, Chang Ma, Xi Cheng, Wei Guo, Sha Li
  Biomedicine & Pharmacotherapy.2025; 188: 118191.     CrossRef
• The Role of Global Physical Capacity Score in Key Parameters of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
  Nicola Verrelli, Caterina Bonfiglio, Isabella Franco, Claudia Beatrice Bagnato, Dolores Stabile, Endrit Shahini, Antonella Bianco
  Journal of Clinical Medicine.2025; 14(11): 3821.     CrossRef
• Evolving Public Attention to Steatotic Liver Disease: A 20‐Year Analysis (2004–2024)
  Pojsakorn Danpanichkul, Charat Thongprayoon, Kanokphong Suparan, Donghee Kim, Ornpailin Wanichthanaolan, Phuuwadith Wattanachayakul, Yanfang Pang, Mark D. Muthiah, Anand V. Kulkarni, Ju Dong Yang, Apichat Kaewdech, Wisit Cheungpasitporn, Karn Wijarnpreech
  Journal of Gastroenterology and Hepatology.2025; 40(8): 2053.     CrossRef
• The association between sedentary behavior and MASLD in overweight and obese adults: investigating the role of inflammatory markers using NHANES data (2017–March 2020)
  Zehong Zhou, Linfang Li, Chusi Wang, Shiqi Li, Pengfei Chen, Jiesheng Huang, Ming Peng
  Frontiers in Nutrition.2025;[Epub]     CrossRef
• Current burden of MASLD, MetALD, and hepatic fibrosis among US adults with prediabetes and diabetes, 2017–2023
  Donghee Kim, Rohit Loomba, Aijaz Ahmed
  Clinical and Molecular Hepatology.2025; 31(3): e235.     CrossRef
• Contemporary burden of mortality from chronic liver disease by sex and race/ethnicity in the United States
  Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
  Clinical and Molecular Hepatology.2025; 31(3): e268.     CrossRef
• Persistent Binge Drinking History Associated With Advanced Liver Fibrosis and All‐Cause Mortality in MetALD
  Zhe‐Kun Xiong, Ru‐Tao Lin, Bi‐Wei Chen, Xin Xin, Tao‐Ying Deng, Qin‐Mei Sun, Yi‐Yang Hu, Li‐Ming Gan, Qin Feng
  Alimentary Pharmacology & Therapeutics.2025; 62(11-12): 1100.     CrossRef
• Advancing Policy and Practice in Alcohol-Associated Liver Disease and Alcohol-Attributable Cancer: Correspondence to the editorial on “Rising Burden of Alcohol-Associated Liver Disease and Cancers: Insights into Sex Disparities and Policy Implications”
  Pojsakorn Danpanichkul, Donghee Kim, Karn Wijarnpreecha, Amit G. Singal, Ju Dong Yang
  Clinical and Molecular Hepatology.2025;[Epub]     CrossRef
• A Novel Risk Prediction Model for Hepatocellular Carcinoma in MASLD: A Multinational, Multicenter Cohort Study
  Ho Soo Chun, Minjong Lee, Hye Ah Lee, Eun Seo Park, Jeong Yoon Choi, Hyo Song Baek, Tae Hun Kim, Huapeng Lin, Terry Cheuk-Fung Yip, Hye Won Lee, Emmanuel Tsochatzis, Salvatore Petta, Elisabetta Bugianesi, Masato Yoneda, Ming-Hua Zheng, Hannes Hagström, Jé
  Clinical Gastroenterology and Hepatology.2025;[Epub]     CrossRef
• Effect of varenicline on major adverse liver outcomes in alcohol‐associated liver disease: An exploratory analysis
  Pojsakorn Danpanichkul, Yanfang Pang, Donghee Kim, Thanathip Suenghataiphorn, Donghyun Ko, Andrew F. Ibrahim, Vitchapong Prasitsumrit, Kwanjit Duangsonk, Mazen Noureddin, Karn Wijarnpreecha, Suthat Liangpunsakul
  Alcohol, Clinical and Experimental Research.2025; 49(11): 2451.     CrossRef
• The effects of ellagic acid in metabolic dysfunction-associated steatotic liver disease (MASLD) patients: a randomized, add-on, double-blind, controlled trial
  Mohammad Mahmoudi Azar, Matin Shirazinia, Mohsen Nematy, Vafa Baradaran Rahimi, Motahare Bateni, Fateme Tafaghodi Piadeh Gheibi, Farnood Rajabzadeh, Ladan Goshayeshi, Sara Honari, Mehran Mottahedi, Vahid Reza Askari
  Inflammopharmacology.2025; 33(9): 5583.     CrossRef
• Dietary vitamin E intake in metabolic dysfunction–associated steatotic liver disease and all-cause/cause-specific mortality
  Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Aijaz Ahmed
  European Journal of Gastroenterology & Hepatology.2025;[Epub]     CrossRef
• Letter to the Editor on “Current Burden of Steatotic Liver Disease and Fibrosis among Adults in the United States, 2017-2023”
  Sisi Yang, Zhenxuan Ma
  Clinical and Molecular Hepatology.2025;[Epub]     CrossRef
• Non‐Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis
  Nadir Abbas, Rachel Smith, Ellina Lytvyak, Miki Scaravaglio, Neil Halliday, Amal Almahroos, Nadia Eden, Diane Lloyd‐Madden, Sanchit Sharma, James Ferguson, Jessica K. Dyson, Douglas Thorburn, David Jones, Aldo J. Montano‐Loza, Marco Carbone, Pietro Invern
  Alimentary Pharmacology & Therapeutics.2025;[Epub]     CrossRef
• Extrahepatic manifestation of metabolic dysfunction-associated steatotic liver disease
  Anoushka Shenoy, Aijaz Ahmed, Donghee Kim
  Metabolism and Target Organ Damage.2025;[Epub]     CrossRef
• Class-Specific Effects of ARBs Versus ACE Inhibitors on Survival and Cardiovascular Outcomes in MASLD
  Tom Ryu, Yeon Joo Seo, Jaejun Lee, Ji Won Han, Hyun Yang, Keungmo Yang
  International Journal of Molecular Sciences.2025; 26(20): 10061.     CrossRef
• Social Determinants of Health in Metabolic Dysfunction‐Associated Steatotic Liver Disease and All‐Cause/Cause‐Specific Mortality
  Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Rohit Loomba, Aijaz Ahmed
  Alimentary Pharmacology & Therapeutics.2025;[Epub]     CrossRef
• Editorial: Understanding How Social Determinants of Health Impact Mortality in MASLD—Insights From a National Analysis. Authors' Reply
  Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Rohit Loomba, Aijaz Ahmed
  Alimentary Pharmacology & Therapeutics.2025;[Epub]     CrossRef

Citations

Citations to this article as recorded by  

• Dietary vitamin E intake in metabolic dysfunction–associated steatotic liver disease and all-cause/cause-specific mortality
  Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Aijaz Ahmed
  European Journal of Gastroenterology & Hepatology.2026; 38(1): 63.     CrossRef
• Phthalates exposure, biological aging, and increased risks of insulin resistance, prediabetes, and diabetes in adults with metabolic dysfunction-associated steatotic liver disease
  Yueru Yang, Shuhui Wan, Linling Yu, Wei Liu, Jiahao Song, Da Shi, Yongfang Zhang, Weihong Chen, Weihong Qiu, Bin Wang
  Diabetes & Metabolism.2025; 51(1): 101602.     CrossRef
• Increased MASH-associated liver cancer in younger demographics
  Pojsakorn Danpanichkul, Yanfang Pang, Kanokphong Suparan, Thanida Auttapracha, Supapitch Sirimangklanurak, Abdelrahman M. Attia, Chanattha Thimphitthaya, Michelle Shi Ni Law, Zhenning Yu, Mostafa A. Soliman, Natchaya Polpichai, Chanakarn Kanitthamniyom, D
  Hepatology Communications.2025;[Epub]     CrossRef
• Alcohol–Related Liver Disease, Followed by Metabolic Dysfunction–Associated Steatotic Liver Disease, Emerges as the Fastest‐Growing Aetiologies for Primary Liver Cancer in the United States
  Pojsakorn Danpanichkul, Kwanjit Duangsonk, Markos Kalligeros, Michael B. Fallon, Chawinthorn Vuthithammee, Chun Wei Pan, Preenapun Saokhieo, William Derrick, Yanfang Pang, Vincent L. Chen, Donghee Kim, Amit G. Singal, Ju Dong Yang, Karn Wijarnpreecha
  Alimentary Pharmacology & Therapeutics.2025; 61(6): 959.     CrossRef
• Current Burden of Lean Metabolic Dysfunction‐Associated Steatotic Liver Disease Among US Adults, 2017–2023
  Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed
  Alimentary Pharmacology & Therapeutics.2025; 61(5): 891.     CrossRef
• Comparative application of MAFLD and MASLD diagnostic criteria on NAFLD patients: insights from a single-center cohort
  Maha Elsabaawy, Madiha Naguib, Ahmed Abuamer, Ahmed Shaban
  Clinical and Experimental Medicine.2025;[Epub]     CrossRef
• Advanced lung cancer inflammation index: a key predictor of hepatic steatosis and fibrosis severity
  Yajie Liu, Ruilin Wang
  BMC Gastroenterology.2025;[Epub]     CrossRef
• Association of High‐Sensitivity Troponins in Metabolic Dysfunction‐Associated Steatotic Liver Disease With All‐Cause and Cause‐Specific Mortality
  Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
  Alimentary Pharmacology & Therapeutics.2025; 61(11): 1785.     CrossRef
• Addressing the burden of steatotic liver disease: The role of transient elastography: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023”
  Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed
  Clinical and Molecular Hepatology.2025; 31(2): e180.     CrossRef
• Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023
  Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed
  Clinical and Molecular Hepatology.2025; 31(2): 382.     CrossRef
• Liver cirrhosis in metabolic dysfunction-associated steatohepatitis
  Donghyun Ko, Do Han Kim, Pojsakorn Danpanichkul, Masahito Nakano, Chitchai Rattananukrom, Karn Wijarnpreecha, Cheng Han Ng, Mark D Muthiah
  Gastroenterology Report.2025;[Epub]     CrossRef
• Advances in identifying risk factors of metabolic dysfunction-associated alcohol-related liver disease
  Rui-Qi Ye, Yi-Fan Chen, Chang Ma, Xi Cheng, Wei Guo, Sha Li
  Biomedicine & Pharmacotherapy.2025; 188: 118191.     CrossRef
• Increased Mortality Among Lean Versus Non‐Lean Adults With MASLD: A Multicenter Study
  Leith Ghani, Majd B. Aboona, Claire S. Faulkner, Pooja Rangan, Moises Nevah Rubin, Ma Ai Thanda Han, Michael B. Fallon, Vincent L. Chen, Karn Wijarnpreecha
  Journal of Gastroenterology and Hepatology.2025; 40(8): 1919.     CrossRef
• Evolving Public Attention to Steatotic Liver Disease: A 20‐Year Analysis (2004–2024)
  Pojsakorn Danpanichkul, Charat Thongprayoon, Kanokphong Suparan, Donghee Kim, Ornpailin Wanichthanaolan, Phuuwadith Wattanachayakul, Yanfang Pang, Mark D. Muthiah, Anand V. Kulkarni, Ju Dong Yang, Apichat Kaewdech, Wisit Cheungpasitporn, Karn Wijarnpreech
  Journal of Gastroenterology and Hepatology.2025; 40(8): 2053.     CrossRef
• Meta‐Analysis: Effects of Steatotic Liver Disease‐Associated Genetic Risk Alleles on Longitudinal Outcomes
  Matthew Kubina, Vitchapong Prasitsumrit, Jarell Tan, Joo Wei Ethan Quek, Dhiraj Peddu, Ankit Mishra, Pojsakorn Danpanichkul, Jake P. Mann, Eric Trépo, Stephan Buch, Daniel Q. Huang, Cheng Han Ng, Mark D. Muthiah, Yu Jun Wong, Karn Wijarnpreecha, Vincent L
  Alimentary Pharmacology & Therapeutics.2025; 62(3): 244.     CrossRef
• Metabolic Impact of Alcohol Consumption in MASLD: Understanding MetALD and Beyond
  Eva Juárez-Hernández, Montserrat Berrospe-Alfaro, Misael Uribe, Iván López-Mendez
  Journal of Clinical and Experimental Hepatology.2025; 15(6): 103114.     CrossRef
• Current burden of MASLD, MetALD, and hepatic fibrosis among US adults with prediabetes and diabetes, 2017–2023
  Donghee Kim, Rohit Loomba, Aijaz Ahmed
  Clinical and Molecular Hepatology.2025; 31(3): e235.     CrossRef
• Predicting the risk of lean non-alcoholic fatty liver disease based on interpretable machine models in a Chinese T2DM population
  Shixue Bao, Qiankai Jin, Tieqiao Wang, Yushan Mao, Guoqing Huang
  Frontiers in Endocrinology.2025;[Epub]     CrossRef
• Effect of varenicline on major adverse liver outcomes in alcohol‐associated liver disease: An exploratory analysis
  Pojsakorn Danpanichkul, Yanfang Pang, Donghee Kim, Thanathip Suenghataiphorn, Donghyun Ko, Andrew F. Ibrahim, Vitchapong Prasitsumrit, Kwanjit Duangsonk, Mazen Noureddin, Karn Wijarnpreecha, Suthat Liangpunsakul
  Alcohol, Clinical and Experimental Research.2025; 49(11): 2451.     CrossRef
• Paradoxical association between steatotic liver disease and favorable hepatic outcomes in HCV patients with SVRs
  Ming-Ling Chang, Jur-Shan Cheng, Jennifer Tai, Wei-Ting Chen, Sien-Sing Yang, Cheng-Hsun Chiu, Rong-Nan Chien, Chia-Lin Hsu, Shang-Jung Wu, Cathy SJ Fann
  Hepatology International.2025;[Epub]     CrossRef
• Extrahepatic manifestation of metabolic dysfunction-associated steatotic liver disease
  Anoushka Shenoy, Aijaz Ahmed, Donghee Kim
  Metabolism and Target Organ Damage.2025;[Epub]     CrossRef
• Obesity-Driven Metabolic Disorders: The Interplay of Inflammation and Mitochondrial Dysfunction
  Wooyoung Choi, Gun Ha Woo, Tae-Hwan Kwon, Jae-Han Jeon
  International Journal of Molecular Sciences.2025; 26(19): 9715.     CrossRef
• Social Determinants of Health in Metabolic Dysfunction‐Associated Steatotic Liver Disease and All‐Cause/Cause‐Specific Mortality
  Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Rohit Loomba, Aijaz Ahmed
  Alimentary Pharmacology & Therapeutics.2025;[Epub]     CrossRef
• Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts
  Zhenyu Huo, Yijun Chen, Yating Huang, Zhirong Yang, Yujun Long, Qian Zhang, Shuohua Chen, Guodong Wang, Shengtao Zhu, Dianjianyi Sun, Canqing Yu, Jun Lv, Liming Li, Ming-Hua Zheng, Shouling Wu, Yuanjie Pang, Shanshan Wu
  Gut.2025; : gutjnl-2025-336127.     CrossRef
• Metabolic dysfunction-associated steatotic liver disease: Prevalence and progression in lean patients
  Gerard Stupecki, Emilia Kowalczyk, Agnieszka Ciba-Stemplewska, Magdalena Dolecka-Ślusarczyk, Iwona Gorczyca-Głowacka
  Polish Annals of Medicine.2025; : 1.     CrossRef
• Increasing Prevalence of Steatotic Liver Disease in a Japanese Health Checkup Population, 2004–2022
  Yuki Nakahata, Takao Miwa, Akihiro Obora, Takao Kojima, Nobuaki Yagi, Masahito Shimizu
  Liver International.2025;[Epub]     CrossRef
• The global landscape of lean metabolic dysfunction-associated steatotic liver disease: insight from Asia and the West
  Hery Djagat Purnomo, Randy Adiwinata, Cecilia Oktaria Permatadewi, Hesti Triwahyu Hutami, Didik Indiarso
  Frontiers in Gastroenterology.2025;[Epub]     CrossRef
• Role of ChREBP–PPARα–FGF21 Axis in Metabolic Dysfunction of MASLD
  Karina Mireya Palacios Girón, Zamira Helena Hernandez Nazara, Montserrat Maldonado-González, Erika Martínez-López, Martha P. Sánchez Muñoz, Carlos Alfredo Bautista López, Ma. Soledad Aldana Aguiñaga, Jose Alfredo Dominguez-Rosales, Belinda Vargas-Guerrero
  International Journal of Molecular Sciences.2025; 26(23): 11425.     CrossRef
• Implication of the Androgen Receptor in Muscle–Liver Crosstalk: An Overlooked Mechanistic Link in Lean-MASLD
  Eleni Myrto Trifylli, Christiana Charalambous, Nikolaos Spiliotopoulos, Nikolaos Papadopoulos, Anastasia Oikonomou, Spilios Manolakopoulos, Melanie Deutsch
  Livers.2025; 5(4): 65.     CrossRef
• PNPLA3 as a driver of steatotic liver disease: navigating from pathobiology to the clinics via epidemiology
  Ralf Weiskirchen, Amedeo Lonardo
  Journal of Translational Genetics and Genomics.2024; 8(4): 355.     CrossRef

Citations

Citations to this article as recorded by  

• Correspondence to letter to the editor on “Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults”
  Chang Hun Lee, In Hee Kim, Sook-Hyang Jeong
  Clinical and Molecular Hepatology.2025; 31(2): e149.     CrossRef

Citations

Citations to this article as recorded by  

• Increased MASH-associated liver cancer in younger demographics
  Pojsakorn Danpanichkul, Yanfang Pang, Kanokphong Suparan, Thanida Auttapracha, Supapitch Sirimangklanurak, Abdelrahman M. Attia, Chanattha Thimphitthaya, Michelle Shi Ni Law, Zhenning Yu, Mostafa A. Soliman, Natchaya Polpichai, Chanakarn Kanitthamniyom, D
  Hepatology Communications.2025;[Epub]     CrossRef

Citations

Citations to this article as recorded by  

• Global Burden, Trends, and Inequalities of Gallbladder and Biliary Tract Cancer, 1990–2021: A Decomposition and Age–Period–Cohort Analysis
  Sen Lei, Guizhong Huang, Xiaohui Li, Pu Xi, Zehui Yao, Xiaojun Lin
  Liver International.2025;[Epub]     CrossRef
• Alcohol–Related Liver Disease, Followed by Metabolic Dysfunction–Associated Steatotic Liver Disease, Emerges as the Fastest‐Growing Aetiologies for Primary Liver Cancer in the United States
  Pojsakorn Danpanichkul, Kwanjit Duangsonk, Markos Kalligeros, Michael B. Fallon, Chawinthorn Vuthithammee, Chun Wei Pan, Preenapun Saokhieo, William Derrick, Yanfang Pang, Vincent L. Chen, Donghee Kim, Amit G. Singal, Ju Dong Yang, Karn Wijarnpreecha
  Alimentary Pharmacology & Therapeutics.2025; 61(6): 959.     CrossRef
• Increased MASH-associated liver cancer in younger demographics
  Pojsakorn Danpanichkul, Yanfang Pang, Kanokphong Suparan, Thanida Auttapracha, Supapitch Sirimangklanurak, Abdelrahman M. Attia, Chanattha Thimphitthaya, Michelle Shi Ni Law, Zhenning Yu, Mostafa A. Soliman, Natchaya Polpichai, Chanakarn Kanitthamniyom, D
  Hepatology Communications.2025;[Epub]     CrossRef
• Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults
  Donghee Kim, Won Kim, Aijaz Ahmed
  Clinical and Molecular Hepatology.2025; 31(1): e5.     CrossRef
• Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populations
  Pojsakorn Danpanichkul, Kanokphong Suparan, Vitchapong Prasitsumrit, Aijaz Ahmed, Karn Wijarnpreecha, Donghee Kim
  Clinical and Molecular Hepatology.2025; 31(1): 74.     CrossRef
• From past to pandemic: Health disparities in US hepatobiliary cancer mortality before and during COVID-19: Editorial on “Burden of mortality from hepatocellular carcinoma and biliary tract cancers by race and ethnicity and sex in US, 2018–2023”
  Ilona Argirion
  Clinical and Molecular Hepatology.2025; 31(1): 286.     CrossRef
• The burden of steatotic liver disease before and during the COVID-19 pandemic: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023”
  Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed
  Clinical and Molecular Hepatology.2025; 31(2): e183.     CrossRef
• Integrating expert knowledge with machine learning for AI-based stroke identifications and treatment systems
  Taddesse kassu Yimenu, Abebe Belay Adege, Sofonias Yitagesu Techan
  DIGITAL HEALTH.2025;[Epub]     CrossRef
• Contemporary burden of mortality from chronic liver disease by sex and race/ethnicity in the United States
  Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
  Clinical and Molecular Hepatology.2025; 31(3): e268.     CrossRef
• Rising drug overdose deaths in chronic liver disease in the United States, 2015–2023
  Donghee Kim, Brittany B Dennis, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
  Clinical and Molecular Hepatology.2025; 31(3): e277.     CrossRef
• Epidemiological trends and burden of gallbladder and biliary tract cancer in Belt and Road Initiative countries: A comprehensive analysis from the Global Burden of Disease 2021 database
  Hao Wu, Qian-Qian Feng, Jian-Hui Li, Hai-Yang Xie, Shi-Gui Yang, Shu-Sen Zheng
  Hepatobiliary & Pancreatic Diseases International.2025;[Epub]     CrossRef
• Extrahepatic manifestation of metabolic dysfunction-associated steatotic liver disease
  Anoushka Shenoy, Aijaz Ahmed, Donghee Kim
  Metabolism and Target Organ Damage.2025;[Epub]     CrossRef
• Paired snRNA-seq and scRNA-seq analysis of MASLD patients to identify early-stage markers for disease progression
  Suebin Park, Su-Hyeon Lee, Se-eun Han, Beom Kyung Kim, Byungjin Hwang
  Hepatology Communications.2025;[Epub]     CrossRef
• Construction and validation of a novel prognostic model for postoperative patients with stage I intrahepatic cholangiocarcinoma: a population-based study
  Xiaomeng Yao, Xinru Fan, Qing Wang, Huabang Zhou, Hui Wang, Heping Hu
  Langenbeck's Archives of Surgery.2025;[Epub]     CrossRef
• Even Lower Alcohol Intake Might Be Harmful for East Asian Males With MASLD Spectrum
  Byungyoon Yun, Juyeon Oh, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin-Ha Yoon
  Clinical Gastroenterology and Hepatology.2025;[Epub]     CrossRef
• Multi-omic analysis reveals elevated BRI3BP expression associated with hepatocellular carcinoma progression and poor prognosis
  Ling Liu, Ye Wang, Jintao Zheng, Lixin Zhou, Chenao Yang, Jiachen Zhang, Changku Jia
  Scientific Reports.2025;[Epub]     CrossRef
• Targeting ferroptosis and cuproptosis in gastrointestinal cancers: molecular mechanisms, metabolic vulnerabilities, and therapeutic interventions
  Yang Zhang, Yixiang Gu, Ming Zhan, Linhua Yang, Hui Wang
  Molecular Biomedicine.2025;[Epub]     CrossRef

Citations

Citations to this article as recorded by  

• Integrative genomic and transcriptomic profiling identifies HSPA5 as a central player in hepatocellular carcinoma pathogenesis
  Taimoor Riaz, Sumbal Rasheed, Muhammad Zubair
  Computational Biology and Chemistry.2026; 120: 108722.     CrossRef
• Diagnostic Test Accuracy of Contrast‐Enhanced Ultrasound With Sonazoid for Assessment of Focal Liver Lesions: A Systematic Review and Meta‐Analysis
  Yongqing Tang, Shun‐ichi Sasaki, Joshua Hawley, Aurélie Peillon, Anders Sjöström, Adolfo Fuentes‐Alburo, Francois Tranquart
  Journal of Clinical Ultrasound.2025; 53(3): 510.     CrossRef
• Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults
  Donghee Kim, Won Kim, Aijaz Ahmed
  Clinical and Molecular Hepatology.2025; 31(1): e5.     CrossRef
• Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populations
  Pojsakorn Danpanichkul, Kanokphong Suparan, Vitchapong Prasitsumrit, Aijaz Ahmed, Karn Wijarnpreecha, Donghee Kim
  Clinical and Molecular Hepatology.2025; 31(1): 74.     CrossRef
• Dual-Functional Micelles for Codelivery of Sorafenib and Dehydrodiisoeugenol in Treatment of Hepatocellular Carcinoma
  Su-Yu Yang, Shu-Tong Li, Tian-Hua Li, De-Jin Ma, Jun-Jie Yu, Yang Liu, Yang Yu, Xue-Tao Li, Juan Zang, Zi-Min Yuan, Liang Kong
  ACS Applied Nano Materials.2025; 8(11): 5355.     CrossRef
• Global burden of HBV-related liver disease: Primary liver cancer due to chronic HBV infection increased in over one-third of countries globally from 2000 to 2021
  Pojsakorn Danpanichkul, Kwanjit Duangsonk, Vincent L. Chen, Preenapun Saokhieo, Disatorn Dejvajara, Banthoon Sukphutanan, Majd B. Aboona, Chawin Lopimpisuth, Yanfang Pang, Andrew F. Ibrahim, Michael B. Fallon, Daniel Q. Huang, Donghee Kim, Amit G. Singal,
  Hepatology.2025; 82(5): 1274.     CrossRef
• A Novel Nuclear-Localized Micropeptide, MP60, Promotes Hepatocellular Carcinoma Progression via the Epithelial-Mesenchymal Transition
  Chencheng Li, Xiu Hong, Sarra Setrerrahmane, Xiaoyi Sun, Xue Zhang, Hanmei Xu
  Cancers.2025; 17(17): 2932.     CrossRef
• MicroRNA-372-3p impairs fatty acid metabolism in hepatocellular carcinoma cells by targeting CPT1A and ACSL4
  Chinnatam Phetkong, Thammachanok Boonto, Pannathon Thamjamrassri, Chaiyaboot Ariyachet, Pisit Tangkijvanich
  BioImpacts.2025; 15: 31075.     CrossRef
• Social Determinants of Health in Metabolic Dysfunction‐Associated Steatotic Liver Disease and All‐Cause/Cause‐Specific Mortality
  Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Rohit Loomba, Aijaz Ahmed
  Alimentary Pharmacology & Therapeutics.2025;[Epub]     CrossRef
• Validation of prognostic models for predicting postsurgical outcomes in intrahepatic cholangiocarcinoma patients using a multicenter cohort
  Dong Hwan Kim, Sang Hyun Choi, Sehee Kim, Woohyung Lee, Hyung-Don Kim, Hyungjin Rhee, Eun-Suk Cho, Suk-Keu Yeom, Sumi Park, Seung Soo Lee, Mi-Suk Park
  International Journal of Surgery.2025; 111(10): 7032.     CrossRef
• Multidisciplinary comprehensive treatment of massive hepatocellular carcinoma with hemorrhage: A case report and review of literature
  Xian-Shuai Kou, Fan-Fan Li, Yun Meng, Jian-Ming Zhao, Sheng-Fen Liu, Lan Zhang
  World Journal of Gastrointestinal Oncology.2024; 16(5): 2225.     CrossRef
• Evaluation of different scoring systems for repeating Transarterial Chemoembolization in Egyptian patients with Hepatocellular Carcinoma
  Omkolsoum Alhaddad, Asmaa Gomaa, Merhan El Shamandy, Mohamed Kohla, Ahmed Edrees, Reham Ashour
  Romanian Journal of Internal Medicine.2024; 62(4): 430.     CrossRef
• Phytochemicals and Their Nanoformulations for Targeting Hepatocellular Carcinoma: Exploring Potential and Targeting Strategies
  Safia Obaidur Rab, R. Roopashree, Farag M. A. Altalbawy, M. Ravi Kumar, Mamata Chahar, Manmeet Singh, Aziz Kubaev, Hassan Thoulfikar A. Alamir, Faraj Mohammed, Abed J. Kadhim, Merwa Alhadrawi
  Cell Biochemistry and Function.2024;[Epub]     CrossRef
• Modulation of gut microbiota by probiotics to improve the efficacy of immunotherapy in hepatocellular carcinoma
  Ping Chen, Chengchen Yang, Ke Ren, Mingzhi Xu, Chenwei Pan, Xuewei Ye, Lanjuan Li
  Frontiers in Immunology.2024;[Epub]     CrossRef
• Current epidemiology of chronic liver disease
  Richie Manikat, Aijaz Ahmed, Donghee Kim
  Gastroenterology Report.2023;[Epub]     CrossRef

Citations

Citations to this article as recorded by  

• Dietary vitamin E intake in metabolic dysfunction–associated steatotic liver disease and all-cause/cause-specific mortality
  Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Aijaz Ahmed
  European Journal of Gastroenterology & Hepatology.2026; 38(1): 63.     CrossRef
• Secondary Growth Hormone Deficiency That Developed into Cirrhosis after Several Years of Interrupted Growth Hormone Replacement Therapy
  Ayana Sueki, Daisuke Kaya, Shinsaku Nagamatsu, Chisa Yamamoto, Kohei Ohta, Yuya Matsuo, Yuya Nishio, Yusuke Komeda, Shoma Kikukawa, Kyohei Matsuura, Hideki Matsuo, Masakazu Uejima, Kei Moriya
  Internal Medicine.2025; 64(3): 387.     CrossRef
• Liver Cancer Risk Across Metabolic Dysfunction-Associated Steatotic Liver Disease and/or Alcohol: A Nationwide Study
  Byungyoon Yun, Heejoo Park, Sang Hoon Ahn, Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon
  American Journal of Gastroenterology.2025; 120(2): 410.     CrossRef
• The Fibrosis-4 index predicts all-cause mortality in a cohort of patients at high cardiovascular risk partly through glomerular filtration rate reduction
  Antonio Mirijello, Gabriella Pacilli, Antonio Siena, Antonio Mangiacotti, Maria Maddalena D'Errico, Daria Dilalla, Olga Lamacchia, Andrea Fontana, Massimiliano Copetti, Pamela Piscitelli, Giovanni Targher, Salvatore A. De Cosmo
  Nutrition, Metabolism and Cardiovascular Diseases.2025; 35(1): 103768.     CrossRef
• Secondhand Smoke Exposure and Metabolic Dysfunction-associated Steatotic Liver Disease in US Adolescents
  Donghee Kim, Brandon J. Perumpail, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Aijaz Ahmed
  Clinical Gastroenterology and Hepatology.2025; 23(4): 665.     CrossRef
• Letter: Towards Better Intervention Strategies for MASLD and MetALD—What Are We Missing? Authors' Reply
  Yewan Park, Jooyi Jung, Gi‐Ae Kim
  Alimentary Pharmacology & Therapeutics.2025; 61(2): 400.     CrossRef
• Red cell distribution width/platelet ratio predicts decompensation of metabolic dysfunction-associated steatotic liver disease-related compensated advanced chronic liver disease
  Ming-Hua Zheng, Amedeo Lonardo
  World Journal of Gastroenterology.2025;[Epub]     CrossRef
• PNPLA3 is one of the bridges between TM6SF2 E167K variant and MASLD: Correspondence to editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD”
  Baokai Sun, Likun Zhuang
  Clinical and Molecular Hepatology.2025; 31(1): e67.     CrossRef
• Role of noninvasive tests on the prediction of hepatocellular carcinoma in nonalcoholic fatty liver disease patients without cirrhosis: a systematic review and meta-analysis of aggregate and individual patient data
  Nanicha Siriwong, Supachaya Sriphoosanaphan, Pakanat Decharatanachart, Tanat Yongpisarn, Stephen J. Kerr, Sombat Treeprasertsuk, Thodsawit Tiyarattanachai, Terapap Apiparakoon, Hannes Hagström, Camilla Akbari, Mattias Ekstedt, Terry Cheuk-Fung Yip, Grace
  European Journal of Gastroenterology & Hepatology.2025; 37(3): 358.     CrossRef
• Unmet needs of metabolic dysfunction – Associated “fatty or steatotic” liver disease
  Yu-Ming Cheng, Shao-Wen Wang, Ching Wang, Chia-Chi Wang
  Tzu Chi Medical Journal.2025; 37(2): 152.     CrossRef
• Association Between Handgrip Strength and Cardiovascular Disease Risk in MASLD: A Prospective Study From UK Biobank
  Tae Seop Lim, Sujin Kwon, Sung A. Bae, Hye Yeon Chon, Seol A. Jang, Ja Kyung Kim, Chul Sik Kim, Seok Won Park, Kyoung Min Kim
  Journal of Cachexia, Sarcopenia and Muscle.2025;[Epub]     CrossRef
• Metabolic dysfunction-associated steatotic liver disease (MASLD): a systemic disease with a variable natural history and challenging management
  Luigi Elio Adinolfi, Aldo Marrone, Luca Rinaldi, Riccardo Nevola, Antonio Izzi, Ferdinando Carlo Sasso
  Exploration of Medicine.2025;[Epub]     CrossRef
• The relationship between serum uric acid level and non-alcoholic fatty liver disease in northern China: a retrospective cohort study
  Qian He, Xinyue Liu, Guoyong Ding, Yiying Wang, Xiaoting Luo, Wenyuan Cao, Weijia Xing
  BMC Public Health.2025;[Epub]     CrossRef
• Novel pyranopyridine derivatives and their radiolabeled nanoconjugates: An augmented approach for targeted cancer theranostics
  Hesham A. Shamsel-Din, Mohamed M. Swidan, Ahmed B. Ibrahim, Mohamed A. Motaleb, Tamer M. Sakr
  Journal of Drug Delivery Science and Technology.2025; 107: 106802.     CrossRef
• Metabolic dysfunction-associated steatotic liver disease in adults
  Daniel Q. Huang, Vincent W. S. Wong, Mary E. Rinella, Jerome Boursier, Jeffrey V. Lazarus, Hannele Yki-Järvinen, Rohit Loomba
  Nature Reviews Disease Primers.2025;[Epub]     CrossRef
• Elevated red blood cell folate levels are associated with metabolic dysfunction-associated steatotic liver disease: results from NHANES 2017–2020
  Xin Liao, Song Yu, Lin Wang, Ruyue Zhang, Ke Yu
  Frontiers in Physiology.2025;[Epub]     CrossRef
• Association of High‐Sensitivity Troponins in Metabolic Dysfunction‐Associated Steatotic Liver Disease With All‐Cause and Cause‐Specific Mortality
  Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
  Alimentary Pharmacology & Therapeutics.2025; 61(11): 1785.     CrossRef
• Addressing the burden of steatotic liver disease: The role of transient elastography: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023”
  Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed
  Clinical and Molecular Hepatology.2025; 31(2): e180.     CrossRef
• The burden of steatotic liver disease before and during the COVID-19 pandemic: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023”
  Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed
  Clinical and Molecular Hepatology.2025; 31(2): e183.     CrossRef
• Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023
  Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed
  Clinical and Molecular Hepatology.2025; 31(2): 382.     CrossRef
• Associations between non-insulin-based insulin resistance surrogate markers and liver-related outcomes in metabolic dysfunction-associated steatotic liver disease: a nationwide cohort study in South Korea
  Sang Yi Moon, Minkook Son, Yeo Wool Kang, Myeongseok Koh, Jong Yoon Lee, Yang Hyun Baek
  BMC Gastroenterology.2025;[Epub]     CrossRef
• Response to the Letter to the Editor: What Is the Optimal Anti‐Diabetic Regimen Among CHB and T2DM Patients?
  Beom Kyung Kim
  Liver International.2025;[Epub]     CrossRef
• The new definition of metabolic dysfunction-associated steatotic liver disease: the role of ultrasound and elastography
  Xinrui Jin, Terry Cheuk-Fung Yip, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Jimmy Che-To Lai
  Ultrasonography.2025; 44(3): 189.     CrossRef
• Association between dietary amino acid intake and the risk of metabolic dysfunction-associated steatotic liver disease
  Ruoqi Zhou, Xinrong Zhang, Xinxin Liu, Rui Huang, Yuwei Wang, Dajing Xia, Xue Li, Yihua Wu, Yu Shi
  Journal of Advanced Research.2025;[Epub]     CrossRef
• Prevalence and Risk Factors of Metabolic-Associated Fatty Liver Disease in Children with Down Syndrome at a Tertiary Care Center
  Maria D. Karaceper, Maria-Jose Villegas, Sanathan Sadh, Sierra Kawesa, Jamie Strain, Asha Nair, Alissa Dupuis, Mary Pothos, Ming-Hua Zheng, Mohit Kehar
  Journal of Clinical Medicine.2025; 14(9): 3239.     CrossRef
• The Role of Global Physical Capacity Score in Key Parameters of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
  Nicola Verrelli, Caterina Bonfiglio, Isabella Franco, Claudia Beatrice Bagnato, Dolores Stabile, Endrit Shahini, Antonella Bianco
  Journal of Clinical Medicine.2025; 14(11): 3821.     CrossRef
• Microwave Thermosphere Ablation Versus Radiofrequency Ablation in Hepatocellular Carcinoma: Optimizing Treatment Strategies for Tumor Size and Malignancy Grade
  Hideyuki Tamai, Jumpei Okamura
  Hepatology Research.2025; 55(9): 1274.     CrossRef
• Association between impaired sensitivity to thyroid hormones and sedentary behavior: a cross-sectional study
  Hangzhou Yang, Jie Kang, Lingkang Dong, Zihan Lin, Qixian Lin, Bo Wu
  Frontiers in Medicine.2025;[Epub]     CrossRef
• ECM formation and degradation during fibrosis, repair, and regeneration
  Alejandro E. Mayorca-Guiliani, Diana Julie Leeming, Kim Henriksen, Joachim Høg Mortensen, Signe Holm Nielsen, Quentin M. Anstee, Arun J. Sanyal, Morten A. Karsdal, Detlef Schuppan
  npj Metabolic Health and Disease.2025;[Epub]     CrossRef
• Current burden of MASLD, MetALD, and hepatic fibrosis among US adults with prediabetes and diabetes, 2017–2023
  Donghee Kim, Rohit Loomba, Aijaz Ahmed
  Clinical and Molecular Hepatology.2025; 31(3): e235.     CrossRef
• The Burden of Nonmalignant Metabolic Dysfunction‐Associated Steatotic Liver Disease in the Western Pacific Region: A Systematic Analysis From 1990 to 2021
  Qichao Ge, Yuan Lin, Mingwang Wang, Jianwei Zhu, Qingqing Zhang, Junjun Wang, Yufei Yang, Hanjing Zhangdi, Yuecheng Guo, Shanjuan Wang, Lungen Lu
  Food Science & Nutrition.2025;[Epub]     CrossRef
• The association between serum pinenes and non-alcoholic fatty liver disease based on the NHANES 2013–2014
  Tuo Xiao, Xue Xing, Lulu Sun, Jin Shang
  Ecotoxicology and Environmental Safety.2025; 302: 118712.     CrossRef
• Long-Term Feasibility and Outcomes of a Digital Health Program to Improve Liver Fat and Cardiometabolic Markers in Individuals With Nonalcoholic Fatty Liver Disease: Prospective Single-Arm Feasibility Study
  Sigridur Björnsdottir, Hildigunnur Ulfsdottir, Elias Freyr Gudmundsson, Bartosz Dobies, Kolbrun Sveinsdottir, Ari Pall Isberg, Gudlaug E A Magnusdottir, Thrudur Gunnarsdottir, Tekla Karlsdottir, Gudlaug Bjornsdottir, Sigurdur Sigurdsson, Saemundur Oddsson
  JMIR Cardio.2025; 9: e72074.     CrossRef
• Reliability of Ultrasonic Hepatorenal Indices in Assessing Hepatic Steatosis: A Systematic Review and Meta‐Analysis
  Jin‐Li Wang, Jian Dong, Si‐Rui Wang, Chun‐Li Cao, Jin Tong, WenXiao Li, Ting‐Ting Du, Ting‐Ting He, Xiao‐Wu Yuan, Jun Li, Hong Zhai
  Journal of Clinical Ultrasound.2025;[Epub]     CrossRef
• The effects of ellagic acid in metabolic dysfunction-associated steatotic liver disease (MASLD) patients: a randomized, add-on, double-blind, controlled trial
  Mohammad Mahmoudi Azar, Matin Shirazinia, Mohsen Nematy, Vafa Baradaran Rahimi, Motahare Bateni, Fateme Tafaghodi Piadeh Gheibi, Farnood Rajabzadeh, Ladan Goshayeshi, Sara Honari, Mehran Mottahedi, Vahid Reza Askari
  Inflammopharmacology.2025; 33(9): 5583.     CrossRef
• Comparison of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Steatotic Liver Disease
  Yunmi Ko, Moon Haeng Hur, Youngsu Park, Jeayeon Park, Hyunjae Shin, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim
  Gut and Liver.2025; 19(5): 758.     CrossRef
• Extrahepatic manifestation of metabolic dysfunction-associated steatotic liver disease
  Anoushka Shenoy, Aijaz Ahmed, Donghee Kim
  Metabolism and Target Organ Damage.2025;[Epub]     CrossRef
• Social Determinants of Health in Metabolic Dysfunction‐Associated Steatotic Liver Disease and All‐Cause/Cause‐Specific Mortality
  Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Rohit Loomba, Aijaz Ahmed
  Alimentary Pharmacology & Therapeutics.2025;[Epub]     CrossRef
• Placebo Rates in Metabolic Dysfunction–Associated Steatohepatitis Clinical Trials: A Systematic Review and Meta-Analysis
  Francisco Idalsoaga, Luis Antonio Díaz, Saleh Alghsoon, Bishoy Lawendy, Neha Sharma, Hailemichael Desalegn, Yuhong Yuan, My Ha, Jessica Le, John K. MacDonald, Marco Arrese, Rohit Loomba, Vipul Jairath, Mohammad Qasim Khan, Juan Pablo Arab
  Clinical Gastroenterology and Hepatology.2025;[Epub]     CrossRef
• Editorial: Understanding How Social Determinants of Health Impact Mortality in MASLD—Insights From a National Analysis. Authors' Reply
  Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Rohit Loomba, Aijaz Ahmed
  Alimentary Pharmacology & Therapeutics.2025;[Epub]     CrossRef
• Quick glance at 'metabolic dysfunction associated steatotic liver disease' therapeutics: Targets, trials, and trends
  George S Zacharia, Muhammad H Ashraf, Franklin Sosa, Anu Jacob, Harish Patel
  World Journal of Gastrointestinal Pharmacology and Therapeutics.2025;[Epub]     CrossRef
• Cost‐effectiveness study of FIB‐4 followed by transient elastography screening strategy for advanced hepatic fibrosis in a NAFLD at‐risk population
  Huiyul Park, Eileen L. Yoon, Mimi Kim, Sun‐Hong Kwon, Donghee Kim, Ramsey Cheung, Hye‐Lin Kim, Dae Won Jun
  Liver International.2024; 44(4): 944.     CrossRef
• Proposal of a Novel Serological Algorithm Combining FIB-4 and Serum M2BPGi for Advanced Fibrosis in Nonalcoholic Fatty Liver Disease
  Sang Yi Moon, Yang Hyun Baek, Se Young Jang, Dae Won Jun, Ki Tae Yoon, Young Youn Cho, Hoon Gil Jo, Ae Jeong Jo
  Gut and Liver.2024; 18(2): 283.     CrossRef
• Editorial: Using machine learning to predict significant fibrosis in metabolic dysfunction‐associated steatotic liver disease
  Richie Manikat, Aijaz Ahmed, Donghee Kim
  Alimentary Pharmacology & Therapeutics.2024; 59(7): 893.     CrossRef
• Steatotic liver disease‐associated all‐cause/cause‐specific mortality in the United States
  Donghee Kim, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
  Alimentary Pharmacology & Therapeutics.2024; 60(1): 33.     CrossRef
• Estimated pulse wave velocity in metabolic dysfunction‐associated steatotic liver disease and all‐cause/cause‐specific mortality
  Donghee Kim, Richie Manikat, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
  Journal of Gastroenterology and Hepatology.2024; 39(9): 1950.     CrossRef
• Perspective article: determinants and assessment of cardiovascular risk in steatotic liver disease owing to metabolic dysfunction-addressing the challenge
  Mohamad Jamalinia, Amedeo Lonardo
  Metabolism and Target Organ Damage.2024;[Epub]     CrossRef
• Accurate prediction of all-cause mortality in patients with metabolic dysfunction-associated steatotic liver disease using electronic health records
  Ignat Drozdov, Benjamin Szubert, Ian A. Rowe, Timothy J. Kendall, Jonathan A. Fallowfield
  Annals of Hepatology.2024; 29(5): 101528.     CrossRef
• The synergistic impact of type 2 diabetes and MASLD on cardiovascular, liver, diabetes‐related and cancer outcomes
  David R. Riley, Theresa Hydes, Gema Hernadez, Sizheng S. Zhao, Uazman Alam, Daniel J. Cuthbertson
  Liver International.2024; 44(10): 2538.     CrossRef
• The Impact of Body Composition on the Prognosis of Nonalcoholic Fatty Liver Disease
  Do Seon Song
  Gut and Liver.2024; 18(4): 562.     CrossRef
• Association of nonalcoholic fatty liver disease with new-onset atrial fibrillation stratified by age groups
  Eun Ju Cho, Goh Eun Chung, Jeong-Ju Yoo, Yuri Cho, Kyu Na Lee, Dong Wook Shin, Yoon Jun Kim, Jung-Hwan Yoon, Kyungdo Han, Su Jong Yu
  Cardiovascular Diabetology.2024;[Epub]     CrossRef
• Metabolic Dysfunction-Associated Steatotic Liver Disease in Japan: Prevalence Trends and Clinical Background in the 10 Years before the Coronavirus Disease 2019 Pandemic
  Akira Sato, Yumiko Oomori, Rika Nakano, Tomokazu Matsuura
  Medicina.2024; 60(8): 1330.     CrossRef
• Contemporary awareness of nonalcoholic fatty liver disease and viral hepatitis based on the stage
  Donghee Kim, Richie Manikat, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
  The American Journal of the Medical Sciences.2024; 368(6): 685.     CrossRef
• High sensitivity troponins and mortality in the population with metabolic dysfunction-associated steatotic liver disease
  Jingjing Hu, Yuteng Du, Yidan Zhou, Huiying Wang
  Scientific Reports.2024;[Epub]     CrossRef
• Impact of Korean Military Service on the Prevalence of Steatotic Liver Disease: A Longitudinal Study of Pre-enlistment and In-Service Health Check-Ups
  Jaejun Lee, Jae Hyeop Jung, Sung Jun Choi, Beomman Ha, Hyun Yang, Pil Soo Sung, Si Hyun Bae, Jeong-A Yu
  Gut and Liver.2024; 18(5): 888.     CrossRef
• Vaccinium spp. Berries in the Prevention and Treatment of Non-Alcoholic Fatty Liver Disease: A Comprehensive Update of Preclinical and Clinical Research
  Ewelina Książek, Zuzanna Goluch, Marta Bochniak
  Nutrients.2024; 16(17): 2940.     CrossRef
• Metabolic bariatric surgery, alcohol misuse and liver cirrhosis: a narrative review
  Matthew L. Basa, Danielle S. Cha, David P. Mitchell, Daniel L. Chan
  Metabolism and Target Organ Damage.2024;[Epub]     CrossRef
• Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study
  Yewan Park, Jooyi Jung, Seungbong Han, Gi‐Ae Kim
  Alimentary Pharmacology & Therapeutics.2024; 60(11-12): 1599.     CrossRef
• Metabolic Dysfunction-Associated Steatotic Liver Disease Is Associated with Increased Risk of Kidney Cancer: A Nationwide Study
  Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon, Hyung Ho Lee, Heejoo Park, Jian Lee, Youngsun Park, Byungyoon Yun, Jinsoo Chung
  Cancers.2024; 16(18): 3161.     CrossRef
• Metabolic-associated fatty liver disease is less effective in predicting mortality than non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease: Letter to the editor on “Prognosis of biopsy-confirmed metabolic dysfun
  Yixuan Zhu, Xiaoyan Ma, Wenjing Ni, Yee Hui Yeo, Junping Shi, Jie Li
  Clinical and Molecular Hepatology.2024; 30(4): 974.     CrossRef
• Leukocyte telomere shortening in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality
  Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
  Clinical and Molecular Hepatology.2024; 30(4): 982.     CrossRef
• Unraveling the Association of Liver Steatosis and Fibrosis with Vitamin B12: A Cross-Sectional Study
  Silvia Espina, Diego Casas-Deza, Vanesa Bernal-Monterde, Ana Royo-Esteban, Maria Pilar García-Sobreviela, Pilar Calmarza, Ana B. Martinez-Martinez, Jesús Osada, Jose M. Arbones-Mainar
  Metabolites.2024; 14(11): 618.     CrossRef
• Association between Body Fat Distribution and Nonalcoholic Fatty Liver Disease/Fibrosis Based on Race/Ethnicity
  Donghee Kim, George Cholankeril, Aijaz Ahmed
  Journal of Obesity & Metabolic Syndrome.2024; 33(4): 326.     CrossRef
• Nonlinear correlation between fatty liver index and carotid intima media thickness among individuals undergoing health examination
  Yuanchen Zhou, Shaojie Duan, Rongrui Wang, Jialiang Chen, Shukun Yao
  Frontiers in Endocrinology.2023;[Epub]     CrossRef
• The growing burden of non-alcoholic fatty liver disease on mortality
  Ju-Yeon Cho, Won Sohn
  Clinical and Molecular Hepatology.2023; 29(2): 374.     CrossRef
• Discovery of new pyridine heterocyclic hybrids; design, synthesis, dynamic simulations, and in vitro and in vivo breast cancer biological assays
  Menna M. Abdelshaheed, Hussein I. El Subbagh, Mohamed A. Tantawy, Reem T. Attia, Khairia M. Youssef, Iten M. Fawzy
  RSC Advances.2023; 13(23): 15689.     CrossRef
• Synergistic Preventive Effect of Aerobic and Resistance Exercises on Nonalcoholic Fatty Liver Disease
  Ju-Yeon Cho, Won Sohn
  Gut and Liver.2023; 17(4): 487.     CrossRef
• Comment on Clayton-Chubb et al. Understanding NAFLD: From Case Identification to Interventions, Outcomes, and Future Perspectives. Nutrients 2023, 15, 687
  Ludovico Abenavoli, Giuseppe La Torre, Natasa Milic
  Nutrients.2023; 15(13): 2907.     CrossRef
• Impact of Health Related QoL and Mediterranean Diet on Liver Fibrosis in Patients with NAFLD
  Nuria Perez-Diaz-del-Campo, Gabriele Castelnuovo, Chiara Rosso, Aurora Nicolosi, Marta Guariglia, Eleonora Dileo, Angelo Armandi, Gian Paolo Caviglia, Elisabetta Bugianesi
  Nutrients.2023; 15(13): 3018.     CrossRef
• Aerobic and Resistance Exercise: Synergistic Influence for Nonalcoholic Fatty Liver Disease
  Ho Soo Chun
  Gut and Liver.2023; 17(4): 485.     CrossRef
• From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials
  Ming-Lun Yeh, Ming-Lung Yu
  Clinical and Molecular Hepatology.2023; 29(4): 969.     CrossRef
• Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity
  Hong-Kyu Kim, Sung-Jin Bae, Min Jung Lee, Eun Hee Kim, Hana Park, Hwi Seung Kim, Yun Kyung Cho, Chang Hee Jung, Woo Je Lee, Jaewon Choe
  Clinical and Molecular Hepatology.2023; 29(4): 987.     CrossRef
• Lifestyle of patients with non-alcoholic fatty liver disease: assessment of dietary habits and physical activity
  T.S. Krolevets, M.I. Syrovenko, M.A. Livzan
  Russian Journal of Evidence-Based Gastroenterology.2023; 12(4): 43.     CrossRef
• Current epidemiology of chronic liver disease
  Richie Manikat, Aijaz Ahmed, Donghee Kim
  Gastroenterology Report.2023;[Epub]     CrossRef

Citations

Citations to this article as recorded by  

• Association Between Sociodemographic Variables, Healthy Habits, and Stress with Risk Scales for Liver Disease Associated with Metabolic Dysfunction
  Ángel Arturo López-González, Emilio Martínez-Almoyna Rifá, Hernán Paublini Oliveira, Cristina Martorell Sánchez, Pedro Juan Tárraga López, José Ignacio Ramírez-Manent
  Life.2025; 15(1): 116.     CrossRef
• Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populations
  Pojsakorn Danpanichkul, Kanokphong Suparan, Vitchapong Prasitsumrit, Aijaz Ahmed, Karn Wijarnpreecha, Donghee Kim
  Clinical and Molecular Hepatology.2025; 31(1): 74.     CrossRef
• Non alkolik yağlı karaciğer hastalığı ile kafein alımı arasındaki ilişki
  İzel Akkaya, İlknur Gökçe Yıldırım
  Sağlık Profesyonelleri Araştırma Dergisi.2025; 7(1): 47.     CrossRef
• Advances in humanoid organoid-based research on inter-organ communications during cardiac organogenesis and cardiovascular diseases
  Baoqiang Ni, Lingqun Ye, Yan Zhang, Shijun Hu, Wei Lei
  Journal of Translational Medicine.2025;[Epub]     CrossRef
• Association of High‐Sensitivity Troponins in Metabolic Dysfunction‐Associated Steatotic Liver Disease With All‐Cause and Cause‐Specific Mortality
  Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
  Alimentary Pharmacology & Therapeutics.2025; 61(11): 1785.     CrossRef
• Investigating the Mechanisms of Lycii fructus in Treating Nonalcoholic Fatty Liver Disease and Diabetes Comorbidity Through Network Pharmacology and Molecular Dynamics
  Peng Sun, Jiahui Song, Yang Liu, Xiujing Li, Yiming Zhang, Yuxing Zhou, Wei Gong
  Food Science & Nutrition.2025;[Epub]     CrossRef
• Increased BMD in SLD Patients Without Advanced Hepatic Fibrosis: Evidence From the NHANES 2017–2020 Database
  Tianhao Wu, Lu Li, Yayuan Mei, Peizhen Lv, Jiawei Cui, Lin Liu, Yuemin Nan, Ang Li, Yu-Chen Fan
  Canadian Journal of Gastroenterology and Hepatology.2025;[Epub]     CrossRef
• Advances in Incretin‐Based Therapies for MAFLD: Mechanisms and Clinical Evidence
  Wenqi Dong, Haiming Zhang, Shaowei Mu, Shuyi Shi, Junli Zhang, Keshu Xu
  Clinical Pharmacology & Therapeutics.2025;[Epub]     CrossRef
• Causal Relationship between Psoriasis and Non-Alcoholic Fatty Liver Disease: A Bidirectional Two-Sample Mendelian Randomization Study
  恒 杨
  Advances in Clinical Medicine.2024; 14(04): 101.     CrossRef
• Non-alcoholic fatty liver disease: a current challenge of interdisciplinary research
  E. V. Biryukova
  Meditsinskiy sovet = Medical Council.2024; (6): 72.     CrossRef
• Association between obesity phenotypes and non-alcoholic fatty liver: a large population- based study
  Farid Najafi, Yahya Pasdar, Mehdi Moradi Nazar, Mitra Darbandi
  BMC Endocrine Disorders.2024;[Epub]     CrossRef
• Masquerading Spleen: A Perplexing Case of Intrahepatic Splenosis Mimicking Hepatocellular Carcinoma
  Noriko Ikeda, Yujo Kawashita, Masaki Tateishi, Takashi Ueda, Junzo Yamaguchi, Yasuo Washida, Yoichi Hachitanda
  Cureus.2024;[Epub]     CrossRef
• Comparative associations of MASLD and MAFLD with the presence and severity of coronary artery calcification
  Min Kyu Kang, Jeong Eun Song, Rohit Loomba, Soo Young Park, Won Young Tak, Young Oh Kweon, Yu Rim Lee, Jung Gil Park
  Scientific Reports.2024;[Epub]     CrossRef
• Association of Physical Activity With Risk of Liver Fibrosis, Sarcopenia, and Cardiovascular Disease in Nonalcoholic Fatty Liver Disease
  Ho Soo Chun, Minjong Lee, Hye Ah Lee, Seo Yeong Oh, Hyo Jeong Baek, Jae Won Moon, Yeon Jeong Kim, Jinha Lee, Hyoeun Kim, Hwi Young Kim, Kwon Yoo, Tae Hun Kim, Seung Up Kim
  Clinical Gastroenterology and Hepatology.2023; 21(2): 358.     CrossRef
• Positive association between nonalcoholic fatty liver disease and growth hormone deficiency in patients with nonfunctioning pituitary adenoma
  Yoon-a Hwang, Hye Won Lee, Sang Hoon Ahn, Eun Jig Lee, Cheol Ryong Ku, Seung Up Kim
  Frontiers in Endocrinology.2023;[Epub]     CrossRef
• Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non‐alcoholic fatty liver disease
  Ho Soo Chun, Minjong Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Yong‐Ho Lee, Ji‐Hye Kim, Seung Up Kim
  Liver International.2023; 43(3): 608.     CrossRef
• Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management
  Sara Battistella, Francesca D’Arcangelo, Marco Grasso, Alberto Zanetto, Martina Gambato, Giacomo Germani, Marco Senzolo, Francesco Paolo Russo, Patrizia Burra
  Clinical and Molecular Hepatology.2023; 29(Suppl): S286.     CrossRef
• Extrahepatic Outcomes of Nonalcoholic Fatty Liver Disease
  Maryam K. Ibrahim, Tracey G. Simon, Mary E. Rinella
  Clinics in Liver Disease.2023; 27(2): 251.     CrossRef
• Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future
  Jung Hwan Yu, Han Ah Lee, Seung Up Kim
  Clinical and Molecular Hepatology.2023; 29(Suppl): S136.     CrossRef
• Screening strategy for non-alcoholic fatty liver disease
  Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto
  Clinical and Molecular Hepatology.2023; 29(Suppl): S103.     CrossRef
• Diabetes and cirrhosis: Current concepts on diagnosis and management
  Laurent Castera, Kenneth Cusi
  Hepatology.2023; 77(6): 2128.     CrossRef
• Clinical and histologic factors associated with discordance between steatosis grade derived from histology vs. MRI‐PDFF in NAFLD
  Beom K. Kim, Nicole Bernstein, Daniel Q. Huang, Nobuharu Tamaki, Kento Imajo, Masato Yoneda, Nancy Sutter, Jinho Jung, Khang Nguyen, Leyna Nguyen, Tracy Le, Egbert Madamba, Lisa Richards, Mark A. Valasek, Cynthia Behling, Claude B. Sirlin, Atsushi Nakajim
  Alimentary Pharmacology & Therapeutics.2023; 58(2): 229.     CrossRef
• MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study
  Eugene Han, Ho Soo Chun, Yong‐ho Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Byung‐Wan Lee, Eun Seok Kang, Bong‐Soo Cha, Sang Hoon Ahn, Seung Up Kim
  Journal of Gastroenterology and Hepatology.2023; 38(9): 1598.     CrossRef
• Regression of nonalcoholic fatty liver disease is associated with reduced risk of incident diabetes: A longitudinal cohort study
  Dong Hyun Sinn, Danbee Kang, Eliseo Guallar, Sung Chul Choi, Yun Soo Hong, Yewan Park, Juhee Cho, Geum-Youn Gwak, Ahmed Mustafa Rashid
  PLOS ONE.2023; 18(7): e0288820.     CrossRef
• Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes
  Tae Seop Lim, Ho Soo Chun, Soon Sun Kim, Ja Kyung Kim, Minjong Lee, Hyo Jung Cho, Seung Up Kim, Jae Youn Cheong
  Gut and Liver.2023; 17(4): 610.     CrossRef
• Magnetic resonance elastography-based prediction model for hepatic decompensation in NAFLD: A multicenter cohort study
  Beom Kyung Kim, Jaclyn Bergstrom, Rohan Loomba, Nobuharu Tamaki, Namiki Izumi, Atsushi Nakajima, Ramazan Idilman, Mesut Gumussoy, Digdem K. Oz, Ayse Erden, Emily Truong, Ju Dong Yang, Mazen Noureddin, Alina M. Allen, Rohit Loomba, Veeral Ajmera
  Hepatology.2023; 78(6): 1858.     CrossRef
• Polycystic ovary syndrome in pediatric obesity and diabetes
  Elena DONDI, Maria TUFANO, Maria C. VIGONE, Laura LUCACCIONI, Gabriella POZZOBON, Graziamaria UBERTINI, Enza MOZZILLO, Maurizio DELVECCHIO
  Minerva Pediatrics.2022;[Epub]     CrossRef
• Mouse liver injury induces hepatic macrophage FGF23 production
  Pradeep Kumar, Yunshan Liu, Yang Shen, Jacquelyn J. Maher, Francesca Cingolani, Mark J. Czaja, Matias A Avila
  PLOS ONE.2022; 17(3): e0264743.     CrossRef
• New Insights into Non-Alcoholic Fatty Liver Disease and Coronary Artery Disease: The Liver-Heart Axis
  Georgiana-Diana Cazac, Cristina-Mihaela Lăcătușu, Cătălina Mihai, Elena-Daniela Grigorescu, Alina Onofriescu, Bogdan-Mircea Mihai
  Life.2022; 12(8): 1189.     CrossRef
• Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review
  Lei Miao, Jing Xu, Giovanni Targher, Christopher D Byrne, Ming-Hua Zheng
  Clinical and Molecular Hepatology.2022; 28(4): 725.     CrossRef
• Ultrasound-Based Hepatic Elastography in Non-Alcoholic Fatty Liver Disease: Focus on Patients with Type 2 Diabetes
  Georgiana-Diana Cazac, Cristina-Mihaela Lăcătușu, Cătălina Mihai, Elena-Daniela Grigorescu, Alina Onofriescu, Bogdan-Mircea Mihai
  Biomedicines.2022; 10(10): 2375.     CrossRef
• Intestinal microbiota in the treatment of metabolically associated fatty liver disease
  Ji-Shuai Wang, Jin-Chun Liu
  World Journal of Clinical Cases.2022; 10(31): 11240.     CrossRef
• A Multidisciplinary Approach and Current Perspective of Nonalcoholic Fatty Liver Disease: A Systematic Review
  Chowdhury F Zaman, Jakia Sultana, Proma Dey, Jui Dutta, Sadia Mustarin, Nuzhat Tamanna, Aditi Roy, Nisha Bhowmick, Mousumi Khanam, Sadia Sultana, Selia Chowdhury, Farjana Khanam, Md Sakibuzzaman, Priyata Dutta
  Cureus.2022;[Epub]     CrossRef
• The Role of Resveratrol in Liver Disease: A Comprehensive Review from In Vitro to Clinical Trials
  Carmine Izzo, Monica Annunziata, Giuseppe Melara, Roberta Sciorio, Marcello Dallio, Mario Masarone, Alessandro Federico, Marcello Persico
  Nutrients.2021; 13(3): 933.     CrossRef
• Risk stratification using sarcopenia status among subjects with metabolic dysfunction‐associated fatty liver disease
  Ho Soo Chun, Mi Na Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim
  Journal of Cachexia, Sarcopenia and Muscle.2021; 12(5): 1168.     CrossRef
• The Association Between Breastfeeding and Nonalcoholic Fatty Liver Disease in Parous Women: A Nation‐wide Cohort Study
  Yewan Park, Dong Hyun Sinn, Joo Hyun Oh, Myung Ji Goh, Kyunga Kim, Wonseok Kang, Yong‐Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Geum‐Youn Gwak
  Hepatology.2021; 74(6): 2988.     CrossRef
• Association between Fasting Ketonuria and Advanced Liver Fibrosis in Non-Alcoholic Fatty Liver Disease Patients without Prediabetes and Diabetes Mellitus
  Kiyoung Lim, Minkyu Kang, Junggil Park
  Nutrients.2021; 13(10): 3400.     CrossRef
• Fatty Liver Index for Predicting Nonalcoholic Fatty Liver Disease in an Asymptomatic Korean Population
  Eun-Ju Cho, Gu-Cheol Jung, Min-Sun Kwak, Jong-In Yang, Jeong-Yoon Yim, Su-Jong Yu, Goh-Eun Chung
  Diagnostics.2021; 11(12): 2233.     CrossRef
• Non‑alcoholic fatty liver disease and hematologic manifestations (Review)
  Vlad Pădureanu, Dalia Dop, Alice Drăgoescu, Rodica Pădureanu, Anca Mușetescu, Laurențiu Nedelcu
  Experimental and Therapeutic Medicine.2021;[Epub]     CrossRef
• Immunity as Cornerstone of Non-Alcoholic Fatty Liver Disease: The Contribution of Oxidative Stress in the Disease Progression
  Marcello Dallio, Moris Sangineto, Mario Romeo, Rosanna Villani, Antonino Davide Romano, Carmelina Loguercio, Gaetano Serviddio, Alessandro Federico
  International Journal of Molecular Sciences.2021; 22(1): 436.     CrossRef
• Nutraceutical correction in the complex non-drug treatment of metabolic syndrome
  L.G. Agasarov, T.V. Apkhanova, V.N. Sergeev, A.D. Fesun, M.M. Krukova, V.A. Vasilyeva, D.B. Kulchitskaya, T.V. Konchugova, G.A. Puzyreva, M.Yu. Yakovlev
  Voprosy kurortologii, fizioterapii i lechebnoi fizicheskoi kul'tury.2021; 98(4): 25.     CrossRef

Citations

Citations to this article as recorded by  

• Correlation between Serum 25 (OH) D Levels with Insulin Resistance and Metabolic Associated Fatty Liver Disease - A Retrospective Study based on Chinese Patients with Newly Diagnosed Type 2 Diabetes Mellitus
  Xin Zhao, Jianbin Sun, Sixu Xin, Xiumei Xu, Xiaomei Zhang
  Current Diabetes Reviews.2025;[Epub]     CrossRef
• The brain-eye-liver axis during spaceflight: implications of hepatic dysfunction in spaceflight associated neuro-ocular syndrome
  Sinem Helvacıoğlu Akyüz, Ben Cools, Joshua Ong, Ethan Waisberg, Ryung Lee, Andrew G. Lee, Mathieu Vinken
  Life Sciences in Space Research.2025; 47: 164.     CrossRef
• Association of 25‐Hydroxyvitamin D With Metabolic Dysfunction‐Associated Fatty Liver Disease: Results From NHANES 2017–2018
  Xiaojuan Rao, Xinxin Zhang, Shuo Li, Bo Huang, Junhe Wang, Jingqiu Cui, Ming Liu, Tiekun Yan, Suraiya Saleem
  International Journal of Endocrinology.2025;[Epub]     CrossRef
• Gut microbiota, vitamin metabolism, and metabolic dysfunction-associated liver disease: mechanisms, interactions, and therapeutic strategies
  YuShuang SU, Min SHI, BangYi YANG, Hong ZHOU
  SCIENTIA SINICA Vitae.2025;[Epub]     CrossRef
• Association of vitamin D levels with metabolic dysfunction-associated fatty liver disease in children aged 12–18 years
  Xuejie Gao, Yuyun Chen, Xinrui Wang, Yuehang Chen, Xiaoyan Chen, Haibo Li, Hong Ye
  Frontiers in Nutrition.2025;[Epub]     CrossRef
• Beyond bones: Revisiting the role of vitamin D in chronic liver disease
  Rodrigo Guerrero-Guerrero, Osvely Mendez-Guerrero, Anaisa Carranza-Carrasco, Farid Tejeda, Astrid Ardon-Lopez, Nalu Navarro-Alvarez
  World Journal of Hepatology.2025;[Epub]     CrossRef
• Vitamin D was Superior to Omega-3 as a Simvastatin Adjuvant in Improving Blood Lipids and Atherogenic Index in Type-I Dyslipidemic Rats
  Devy LIANTO, Yulia Yusrini DJABIR, Bethania Octaresya MUSTAMU, Aryadi ARSYAD
  Turkish Journal of Pharmaceutical Sciences.2024; 20(6): 390.     CrossRef
• Effects of plant natural products on metabolic-associated fatty liver disease and the underlying mechanisms: a narrative review with a focus on the modulation of the gut microbiota
  Tianqi Cai, Xinhua Song, Xiaoxue Xu, Ling Dong, Shufei Liang, Meiling Xin, Yuhong Huang, Linghui Zhu, Tianxing Li, Xueke Wang, Yini Fang, Zhengbao Xu, Chao Wang, Meng Wang, Jingda Li, Yanfei Zheng, Wenlong Sun, Lingru Li
  Frontiers in Cellular and Infection Microbiology.2024;[Epub]     CrossRef
• Overall and Sex-Specific Associations of Serum Lipid-Soluble Micronutrients with Metabolic Dysfunction-Associated Steatotic Liver Disease among Adults in the United States
  Weiwen Chai, Meng-Hua Tao
  Nutrients.2024; 16(8): 1242.     CrossRef
• Serum 25-hydroxyvitamin D levels and the risk of non-alcoholic fatty liver
  Qi Sheng, Huanchen Shi, Shousheng Liu, Likun Zhuang, Zhenzhen Zhao, Yongning Xin
  Saudi Journal of Gastroenterology.2023; 29(1): 39.     CrossRef
• Relationship Between Vitamin D Deficiency and Non-alcoholic Fatty Liver Disease: A Cross-Sectional Study From a Tertiary Care Center in Northern India
  Manoj Kumar, Ashwin Parchani, Ravi Kant, Arindam Das
  Cureus.2023;[Epub]     CrossRef
• Vitamin D/vitamin D receptor pathway in non-alcoholic fatty liver disease
  Jingqi Liu, Yang Song, Ye Wang, Huashan Hong
  Expert Opinion on Therapeutic Targets.2023; 27(11): 1145.     CrossRef
• Calcifediol During Pregnancy Improves Maternal and Fetal Availability of Vitamin D Compared to Vitamin D3 in Rats and Modifies Fetal Metabolism
  Antonio Gázquez, María Sánchez-Campillo, Alejandro Barranco, Ricardo Rueda, Jia P. Chan, Matthew J. Kuchan, Elvira Larqué
  Frontiers in Nutrition.2022;[Epub]     CrossRef
• The Role of Vitamin D and Vitamin D Binding Protein in Chronic Liver Diseases
  Tudor Lucian Pop, Claudia Sîrbe, Gabriel Benţa, Alexandra Mititelu, Alina Grama
  International Journal of Molecular Sciences.2022; 23(18): 10705.     CrossRef
• Vitamin D levels are not associated with non-alcoholic fatty liver disease severity in a Brazilian population
  Jeniffer Danielle M. Dutra, Quelson Coelho Lisboa, Silvia Marinho Ferolla, Carolina Martinelli M. L. Carvalho, Camila Costa M. Mendes, Teresa Cristina A. Ferrari, Cláudia Alves Couto
  International Journal for Vitamin and Nutrition Research.2021; 91(5-6): 411.     CrossRef
• A randomized controlled clinical trial comparing calcitriol versus cholecalciferol supplementation to reduce insulin resistance in patients with non-alcoholic fatty liver disease
  Laleh Mahmoudi, Sara Asadi, Zahra Al-Mousavi, Ramin Niknam
  Clinical Nutrition.2021; 40(5): 2999.     CrossRef
• Body weight gain rather than body weight variability is associated with increased risk of nonalcoholic fatty liver disease
  Eun Ju Cho, Su Jong Yu, Gu Cheol Jung, Min-Sun Kwak, Jong In Yang, Jeong Yoon Yim, Goh Eun Chung
  Scientific Reports.2021;[Epub]     CrossRef
• To the question of the pathogenetic mechanisms of the influence of obesity on the level of vitamin D
  L. A. Suplotova, V. A. Avdeeva, L. Y. Rozhinskaya
  Obesity and metabolism.2021; 18(2): 169.     CrossRef
• Low Vitamin D Level was Associated with Non-alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus
  Vahid Sheikhi, Zahra Heidari
  Shiraz E-Medical Journal.2021;[Epub]     CrossRef
• Association and interaction between vitamin D level and metabolic syndrome for non-alcoholic fatty liver disease
  Salam Bennouar, Abdelghani Bachir Cherif, Amel Kessira, Djamel Eddine Bennouar, Samia Abdi
  Journal of Diabetes & Metabolic Disorders.2021; 20(2): 1309.     CrossRef
• Fatty Liver Index for Predicting Nonalcoholic Fatty Liver Disease in an Asymptomatic Korean Population
  Eun-Ju Cho, Gu-Cheol Jung, Min-Sun Kwak, Jong-In Yang, Jeong-Yoon Yim, Su-Jong Yu, Goh-Eun Chung
  Diagnostics.2021; 11(12): 2233.     CrossRef
• Associations of Dietary Lipid-Soluble Micronutrients with Hepatic Steatosis among Adults in the United States
  Weiwen Chai, Sarah Eaton, Heather E. Rasmussen, Meng-Hua Tao
  Biomedicines.2021; 9(9): 1093.     CrossRef
• Association between advanced fibrosis in fatty liver disease and overall mortality based on body fat distribution
  Goh Eun Chung, Nam Ju Heo, Donghee Kim, Min‐Sun Kwak, Jeong Yoon Yim, Joo Sung Kim, Aijaz Ahmed
  Journal of Gastroenterology and Hepatology.2020; 35(1): 90.     CrossRef
• A genome-wide association study on liver enzymes in Korean population
  Ji Yeon Seo, Jong-Eun Lee, Goh Eun Chung, Eunsoon Shin, Min-Sun Kwak, Jong In Yang, Jeong Yoon Yim, Zongli Xu
  PLOS ONE.2020; 15(2): e0229374.     CrossRef
• The risk of atrial fibrillation in patients with non-alcoholic fatty liver disease and a high hepatic fibrosis index
  Hyo Eun Park, Heesun Lee, Su-Yeon Choi, Hua Sun Kim, Goh Eun Chung
  Scientific Reports.2020;[Epub]     CrossRef
• Nonalcoholic Fatty Liver Disease Is Associated with Benign Prostate Hyperplasia
  Goh Eun Chung, Jeong Yoon Yim, Donghee Kim, Min-Sun Kwak, Jong In Yang, Boram Park, Seong Joon An, Joo Sung Kim
  Journal of Korean Medical Science.2020;[Epub]     CrossRef
• Vitamin D supplementation for nonalcoholic fatty liver disease in type 2 diabetes mellitus
  Shengju Wang, Baochao Cai, Xuke Han, Yang Gao, Xiaoran Zhang, Ruili Wang, Yuan Zhang, Qiu Chen
  Medicine.2020; 99(19): e20148.     CrossRef
• Correlation between serum 25‑OH vitamin D expression and non‑alcoholic fatty liver disease
  Jiayan Cai, Zhenyu Zhang, Jingqi Liu, Xueling Xiao, Chizhen Wang, Manxiang Deng, Luling Chen
  Experimental and Therapeutic Medicine.2020;[Epub]     CrossRef
• Is vitamin D receptor a druggable target for non-alcoholic steatohepatitis?
  Ying Cao, Xiang-Bing Shu, Zemin Yao, Guang Ji, Li Zhang
  World Journal of Gastroenterology.2020; 26(38): 5812.     CrossRef
• The association of genetic polymorphisms with nonalcoholic fatty liver disease in a longitudinal study
  Goh Eun Chung, Eunsoon Shin, Min-Sun Kwak, Jong In Yang, Jong-Eun Lee, Eun Kyung Choe, Jeong Yoon Yim
  BMC Gastroenterology.2020;[Epub]     CrossRef
• Clinical significance of hepatic steatosis according to coronary plaque morphology: assessment using controlled attenuation parameter
  Hyo Eun Park, Heesun Lee, Su-Yeon Choi, Min-Sun Kwak, Jong In Yang, Jeong Yoon Yim, Goh Eun Chung
  Journal of Gastroenterology.2019; 54(3): 271.     CrossRef
• Dietary patterns are associated with the prevalence of nonalcoholic fatty liver disease in Korean adults
  Goh Eun Chung, Jiyoung Youn, Young Sun Kim, Jung Eun Lee, Sun Young Yang, Joo Hyun Lim, Ji Hyun Song, Eun Young Doo, Joo Sung Kim
  Nutrition.2019; 62: 32.     CrossRef
• Vitamin D status and non-alcoholic fatty liver disease in patients with type 1 diabetes
  E. Cipponeri, N. Vitturi, V. Mariano, F. Boscari, S. Galasso, C. Crepaldi, G. P. Fadini, S. Vigili de Kreutzenberg, M. C. Marescotti, E. Iori, F. Cavallin, L. Sartori, A. Baritussio, A. Avogaro, D. Bruttomesso
  Journal of Endocrinological Investigation.2019; 42(9): 1099.     CrossRef
• Association between Vitamin D Status and Non-Alcoholic Fatty Liver Disease: A Population-Based Study
  Shiying LIU, Yuxiu LIU, Bo WAN, Haoyang ZHANG, Sumei WU, Zheng ZHU, Yanjie LIN, Mingfang WANG, Nanwen ZHANG, Su LIN, Yueyong ZHU
  Journal of Nutritional Science and Vitaminology.2019; 65(4): 303.     CrossRef
• Short-term Dietary Interventions for the Management of Nonalcoholic Fatty Liver
  Caroline S. Stokes, Frank Lammert, Marcin Krawczyk
  Current Medicinal Chemistry.2019; 26(19): 3483.     CrossRef
• Association between Vitamin D Levels and Nonalcoholic Fatty Liver Disease: Potential Confounding Variables
  Lucia Pacifico, John F. Osborn, Enea Bonci, Pasquale Pierimarchi, Claudio Chiesa
  Mini-Reviews in Medicinal Chemistry.2019; 19(4): 310.     CrossRef
• The relationship between 25-hydroxyvitamin D concentration and liver enzymes in overweight or obese adults: Cross-sectional and interventional outcomes
  Negar Naderpoor, Aya Mousa, Maximilian de Courten, Robert Scragg, Barbora de Courten
  The Journal of Steroid Biochemistry and Molecular Biology.2018; 177: 193.     CrossRef
• Nonalcoholic fatty liver disease and advanced fibrosis are associated with left ventricular diastolic dysfunction
  Goh Eun Chung, Jeong-Hoon Lee, Heesun Lee, Min Kyung Kim, Jeong Yoon Yim, Su-Yeon Choi, Yoon Jun Kim, Jung-Hwan Yoon, Donghee Kim
  Atherosclerosis.2018; 272: 137.     CrossRef
• Vitamin D and the Liver—Correlation or Cause?
  Jeremy T. Keane, Harendran Elangovan, Rebecca A. Stokes, Jenny E. Gunton
  Nutrients.2018; 10(4): 496.     CrossRef
• Alcoholic liver disease and vitamin D deficiency
  Gianni Testino, Silvia Leone, Sharmila Fagoonee
  Minerva Medica.2018;[Epub]     CrossRef
• Vitamin D and Related Deficiencies, Sarcopenia and Visceral Obesity in Obese People with NAFLD
  Mihaela Petrova
  Gastroenterology & Hepatology: Open Access.2018;[Epub]     CrossRef
• Reply to: “The association between sarcopenia and non-alcoholic fatty liver disease”
  Bo Kyung Koo, Donghee Kim, Sae Kyung Joo, Jung Ho Kim, Mee Soo Chang, Byeong Gwan Kim, Kook Lae Lee, Won Kim
  Journal of Hepatology.2017; 66(1): 244.     CrossRef
• Is Vitamin D an Independent Risk Factor of Nonalcoholic Fatty Liver Disease?: a Cross-Sectional Study of the Healthy Population
  Danbee Park, Hyuktae Kwon, Seung-Won Oh, Hee-Kyung Joh, Seung-sik Hwang, Jin Ho Park, Jae Moon Yun, Hyejin Lee, Goh Eun Chung, Sangjoon Ze, Jae Hong Park, Yeseul Bae, Arang Lee
  Journal of Korean Medical Science.2017; 32(1): 95.     CrossRef
• Vitamin D in liver disease: Current evidence and potential directions
  Harendran Elangovan, Sarinder Chahal, Jenny E. Gunton
  Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2017; 1863(4): 907.     CrossRef
• Association between nephrolithiasis and fatty liver detected on non-enhanced CT for clinically suspected renal colic
  Abdel-Rauf Zeina, Limor Goldenberg, Alicia Nachtigal, Rabea Hasadia, Walid Saliba
  Clinical Imaging.2017; 43: 148.     CrossRef
• The Association between Vitamin D Insufficiency and Nonalcoholic Fatty Liver Disease: A Population-Based Study
  Yeonjung Ha, Seong Hwang, Kyu Rim
  Nutrients.2017; 9(8): 806.     CrossRef
• Active form of vitamin D ameliorates non-alcoholic fatty liver disease by alleviating oxidative stress in a high-fat diet rat model
  Chong-gui Zhu, Ya-xin Liu, Hao Wang, Bao-ping Wang, Hui-qi Qu, Bao-li Wang, Mei Zhu
  Endocrine Journal.2017; 64(7): 663.     CrossRef
• Development of chronic kidney disease in patients with non-alcoholic fatty liver disease: A cohort study
  Dong Hyun Sinn, Danbee Kang, Hye Ryoun Jang, Seonhye Gu, Soo Jin Cho, Seung Woon Paik, Seungho Ryu, Yoosoo Chang, Mariana Lazo, Eliseo Guallar, Juhee Cho, Geum-Youn Gwak
  Journal of Hepatology.2017; 67(6): 1274.     CrossRef
• Pleiotropic protective effects of Vitamin D against high fat diet-induced metabolic syndrome in rats: One for all
  Dalia K. Mostafa, Rasha A. Nasra, Noha Zahran, Mohammed T. Ghoneim
  European Journal of Pharmacology.2016; 792: 38.     CrossRef
• Docosahexanoic Acid Plus Vitamin D Treatment Improves Features of NAFLD in Children with Serum Vitamin D Deficiency: Results from a Single Centre Trial
  Claudia Della Corte, Guido Carpino, Rita De Vito, Cristiano De Stefanis, Anna Alisi, Stefano Cianfarani, Diletta Overi, Antonella Mosca, Laura Stronati, Salvatore Cucchiara, Massimiliano Raponi, Eugenio Gaudio, Christopher D. Byrne, Valerio Nobili, Jee-Fu
  PLOS ONE.2016; 11(12): e0168216.     CrossRef
• Metabolic aspects of adult patients with nonalcoholic fatty liver disease
  Ludovico Abenavoli, Natasa Milic, Laura Di Renzo, Tomislav Preveden, Milica Medić-Stojanoska, Antonino De Lorenzo
  World Journal of Gastroenterology.2016; 22(31): 7006.     CrossRef
• Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions
  Maria Grazia Clemente, Claudia Mandato, Marco Poeta, Pietro Vajro
  World Journal of Gastroenterology.2016; 22(36): 8078.     CrossRef

Citations

Citations to this article as recorded by  

• Bilirubin bioconversion to urobilin in the gut-liver-kidney axis: A biomarker for insulin resistance in the Cardiovascular-Kidney-Metabolic (CKM) Syndrome
  Zachary A. Kipp, Olufunto O. Badmus, David E. Stec, Brantley Hall, Terry D. Hinds
  Metabolism.2025; 163: 156081.     CrossRef
• Exosomal miRNA combined with anti-inflammatory hyaluronic acid-based 3D bioprinted hepatic patch promotes metabolic reprogramming in NAFLD-mediated fibrosis
  Triya Saha, Shreya Mehrotra, Purva Gupta, Ashok Kumar
  Biomaterials.2025; 318: 123140.     CrossRef
• Hepatoprotective and Fat-Accumulation-Reductive Effects of Curcumin on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
  Jasmine Harumi Sabini, Kris Herawan Timotius
  Current Issues in Molecular Biology.2025; 47(3): 159.     CrossRef
• Rat Model of Endogenous and Exogenous Hyperammonaemia Induced by Different Diets
  Janine Donaldson, Tomasz Jacek, Piotr Wychowański, Kamil Zaworski, Dominika Szkopek, Jarosław Woliński, Danica Grujic, Stefan Pierzynowski, Kateryna Pierzynowska
  International Journal of Molecular Sciences.2025; 26(5): 1818.     CrossRef
• Circulating Bilirubin Levels, but Not Their Genetic Determinants, Are Inversely Associated with Steatotic Liver Disease in Adolescents
  José Patricio Miranda, Juan Cristóbal Gana, Gigliola Alberti, Karen Galindo, Ana Pereira, José Luis Santos
  International Journal of Molecular Sciences.2025; 26(7): 2980.     CrossRef
• Bilirubin metabolism in relation to cancer
  Fengyun Yi, Siyu Tao, Hongze Wu
  Frontiers in Oncology.2025;[Epub]     CrossRef
• Triglyceride-glucose index in the prediction of acute kidney injury in patients undergoing coronary artery bypass surgery
  Chen Li, Xingping Lv, Yezhou Shen, Wei Zhou, Tuo Shen, Guoliang Fan, Feng Zhu
  Frontiers in Cardiovascular Medicine.2025;[Epub]     CrossRef
• Bilirubin metabolism and its application in disease prevention: mechanisms and research advances
  Yue Zhang, Haoni Luan, Peng Song
  Inflammation Research.2025;[Epub]     CrossRef
• The Significance of the Presence of Gilbert's Syndrome in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Retrospective Cohort Study
  Arjuna P De Silva, Krishanni Prabagar, Anuradha S Wickramasinghage, Aruni A Wanniarachchi, Dileepa S Ediriweera, Madunil A Niriella, Hithanadura J De Silva
  Cureus.2025;[Epub]     CrossRef
• Association between polycyclic aromatic hydrocarbons exposure and metabolic dysfunction-associated steatotic liver disease in US adults
  Jiajun Wu, Shaoqian Cui, Xuekui Li, Xiaofei Zhang, Siqi Yang, Junhao Sun, Xiubo Jiang
  Frontiers in Public Health.2025;[Epub]     CrossRef
• Non-linear associations of circulating total bilirubin concentration with the risk of nonalcoholic fatty liver disease and all-cause mortality
  Hui Han, Qingtao Yu, Nina Qin, Bin Song, Yan Meng, Zuojing Feng, Zhaoping Li, Liyong Chen
  Annals of Hepatology.2024; 29(2): 101177.     CrossRef
• Inverse association between total bilirubin and type 2 diabetes in U.S. South Asian males but not females
  Aayush Visaria, Alka Kanaya, Soko Setoguchi, Meghana Gadgil, Jaya Satagopan, Fredirick Lazaro mashili
  PLOS ONE.2024; 19(2): e0297685.     CrossRef
• Hepatotoxicity induced in rats by chronic exposure to F–53B, an emerging replacement of perfluorooctane sulfonate (PFOS)
  Xiaohan Li, Qian Zhang, Aiqing Wang, Shan Shan, Xueying Wang, Yarong Wang, Jianmei Wan, Ping Ning, Chengjiao Hong, Hailin Tian, Yun Zhao
  Environmental Pollution.2024; 346: 123544.     CrossRef
• 5-Aminoimidazole-4-carboxamide-1-β-D-ribofuranoside Attenuates High Fat, High Fructose Diet-induced Fatty Liver and Fibrosis in Mice.
  Ajay Krishnan U, Anuradha Carani Venkataraman
  Biomedical and Pharmacology Journal.2024; 17(1): 383.     CrossRef
• LivMarX: An Optimized Low-Cost Predictive Model Using Biomarkers for Interpretable Liver Cirrhosis Stage Classification
  Sudiksha Kottachery Kamath, Sanjeev Kushal Pendekanti, Divya Rao
  IEEE Access.2024; 12: 92506.     CrossRef
• Heme (dys)homeostasis and liver disease
  Tiago L. Duarte, Nicole Viveiros, Catarina Godinho, Delfim Duarte
  Frontiers in Physiology.2024;[Epub]     CrossRef
• Contribution of Sex Differences to Development of Cardiovascular Disease in Metabolic-Associated Steatotic Liver Disease (MASLD)
  Lucy C. Taylor, Gertrude Arthur, Marcella de Carvalho Cruz, David E. Stec, Olufunto O. Badmus
  International Journal of Translational Medicine.2024; 4(4): 782.     CrossRef
• Bilirubin Levels Are Negatively Correlated with Adiposity in Obese Men and Women, and Its Catabolized Product, Urobilin, Is Positively Associated with Insulin Resistance
  Zachary A. Kipp, Mei Xu, Evelyn A. Bates, Wang-Hsin Lee, Philip A. Kern, Terry D. Hinds
  Antioxidants.2023; 12(1): 170.     CrossRef
• Dietary fiber intake and non-alcoholic fatty liver disease: The mediating role of obesity
  Yu Zhu, Hu Yang, Yaozong Zhang, Songxian Rao, Yufeng Mo, Honghua Zhang, Shaoxian Liang, Zhuang Zhang, Wanshui Yang
  Frontiers in Public Health.2023;[Epub]     CrossRef
• Suppressing Hepatic UGT1A1 Increases Plasma Bilirubin, Lowers Plasma Urobilin, Reorganizes Kinase Signaling Pathways and Lipid Species and Improves Fatty Liver Disease
  Evelyn A. Bates, Zachary A. Kipp, Genesee J. Martinez, Olufunto O. Badmus, Mangala M. Soundarapandian, Donald Foster, Mei Xu, Justin F. Creeden, Jennifer R. Greer, Andrew J. Morris, David E. Stec, Terry D. Hinds
  Biomolecules.2023; 13(2): 252.     CrossRef
• Association of per- and polyfluoroalkyl substance exposure with fatty liver disease risk in US adults
  Xinyuan Zhang, Longgang Zhao, Alan Ducatman, Chuanjie Deng, Katherine Ellen von Stackelberg, Christopher J. Danford, Xuehong Zhang
  JHEP Reports.2023; 5(5): 100694.     CrossRef
• Nanodrug Delivery Systems for Metabolic Chronic Liver Diseases: Advances and Perspectives
  Foteini Athanasopoulou, Michail Manolakakis, Santiago Vernia, Nazila Kamaly
  Nanomedicine.2023; 18(1): 67.     CrossRef
• Assessing the causal relationships between human blood metabolites and the risk of NAFLD: A comprehensive mendelian randomization study
  Ziwei Guo, Tingyu Zhang, Zhangjun Yun, Qian Jin, Xu Cao, Deming Kong, Yuhao Yao, Xiaoke Li, Jiaxin Zhang, Yong’An Ye
  Frontiers in Genetics.2023;[Epub]     CrossRef
• Association between remnant lipoprotein cholesterol levels and risk of non-alcoholic fatty liver disease in non-obese populations: a Chinese longitudinal prospective cohort study
  Yanju Miao, Hong Tao
  BMJ Open.2023; 13(5): e069440.     CrossRef
• A low‐energy total diet replacement program demonstrates a favorable safety profile and improves liver disease severity in nonalcoholic steatohepatitis
  Dimitrios A. Koutoukidis, Ferenc E. Mozes, Susan A. Jebb, Jeremy W. Tomlinson, Michael Pavlides, Francesca Saffioti, Rosemary Huntriss, Paul Aveyard, Jeremy F. Cobbold
  Obesity.2023; 31(7): 1767.     CrossRef
• Hyperbilirubinemia in hospitalized patients: Etiology and outcomes
  Joshua Y Kwon, Paul J Nietert, Don C Rockey
  Journal of Investigative Medicine.2023; 71(7): 773.     CrossRef
• The relationship of serum bilirubin level with histopathological parameters in patients with nonalcoholic fatty liver disease
  Ali KIRIK, Cemal Nuri ERCİN, Hasan GÜREL, Ali Fuat ÇİÇEK, Ali Cem YEKDEŞ, Sultan TÜREL, Serkan TAPAN, Teoman DOĞRU
  DAHUDER Medical Journal.2023; 3(3): 91.     CrossRef
• Impact of obesity on liver function tests: is nonalcoholic fatty liver disease the only player? A review article
  Mervat M. El-Eshmawy
  Porto Biomedical Journal.2023;[Epub]     CrossRef
• Bilirubin represents a negative regulator of ILC2 in allergic airway inflammation
  Juan He, Guanmin Jiang, Xing Li, Qiang Xiao, Yingying Chen, Haixu Xu, Gaoyu Liu, Aihua Lei, Pan Zhou, Kun Shi, Quan Yang, Meng Zhao, Zhi Yao, Jie Zhou
  Mucosal Immunology.2022; 15(2): 314.     CrossRef
• Heme-oxygenase and lipid mediators in obesity and associated cardiometabolic diseases: Therapeutic implications
  John A. McClung, Lior Levy, Victor Garcia, David E. Stec, Stephen J. Peterson, Nader G. Abraham
  Pharmacology & Therapeutics.2022; 231: 107975.     CrossRef
• Multiomics Analysis Reveals the Impact of Microbiota on Host Metabolism in Hepatic Steatosis
  Mujdat Zeybel, Muhammad Arif, Xiangyu Li, Ozlem Altay, Hong Yang, Mengnan Shi, Murat Akyildiz, Burcin Saglam, Mehmet Gokhan Gonenli, Buket Yigit, Burge Ulukan, Dilek Ural, Saeed Shoaie, Hasan Turkez, Jens Nielsen, Cheng Zhang, Mathias Uhlén, Jan Borén, Ad
  Advanced Science.2022;[Epub]     CrossRef
• Serum Bilirubin Level Is Increased in Metabolically Healthy Obesity
  Jing Fu, Qiu Wang, Lin Zhang, Jia Liu, Guang Wang
  Frontiers in Endocrinology.2022;[Epub]     CrossRef
• Hepatoprotection of Probiotics Against Non-Alcoholic Fatty Liver Disease in vivo: A Systematic Review
  Faezah Sabirin, Siong Meng Lim, Chin Fen Neoh, Kalavathy Ramasamy
  Frontiers in Nutrition.2022;[Epub]     CrossRef
• Assessment of efficacy and safety of two Egyptian protocols for treatment-experienced HCV patients: an observational study
  Radwa Samir Hagag, Morkoss Medhat Fakhry, Ossama Ashraf Ahmed, Shaimaa Abdalaleem Abdalgeleel, Mahasen Aly Radwan, Gina Gamal Naguib
  The Egyptian Journal of Internal Medicine.2022;[Epub]     CrossRef
• Association of Serum Bilirubin With Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
  Chen Liang, Zhiyuan Yu, Li Bai, Wei Hou, Shan Tang, Wei Zhang, Xinyue Chen, Zhongjie Hu, Zhongping Duan, Sujun Zheng
  Frontiers in Endocrinology.2022;[Epub]     CrossRef
• Elevated alpha-fetoprotein in asymptomatic adults: Clinical features, outcome, and association with body composition
  Sangmi Jang, Gwang Hyeon Choi, Won Chang, Eun Sun Jang, Jin-Wook Kim, Sook-Hyang Jeong, Nobuyuki Takahashi
  PLOS ONE.2022; 17(7): e0271407.     CrossRef
• Effects of Vitamin E on Neonatal Hyperbilirubinemia in Preterm Newborns
  Behzad Barekatain, Alireza Sadeghnia, Nahid Moradi, Maryam Yazdi
  Advanced Biomedical Research.2022; 11(1): 86.     CrossRef
• Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways
  Olufunto O. Badmus, Sarah A. Hillhouse, Christopher D. Anderson, Terry D. Hinds, David E. Stec
  Clinical Science.2022; 136(18): 1347.     CrossRef
• Higher Adherence to Healthy Lifestyle Score Is Associated with Lower Odds of Non-Alcoholic Fatty Liver Disease
  Yu Zhu, Hu Yang, Shaoxian Liang, Honghua Zhang, Yufeng Mo, Songxian Rao, Yaozong Zhang, Zhuang Zhang, Weiqiang Wang, Wanshui Yang
  Nutrients.2022; 14(21): 4462.     CrossRef
• Role of Seaweeds in Drug Induced Nephrotoxicity
  Nida SOHAİL, Hafiza FARHAT
  Marine Science and Technology Bulletin.2022; 11(4): 515.     CrossRef
• Novel Function for Bilirubin as a Metabolic Signaling Molecule: Implications for Kidney Diseases
  David E. Stec, Claudio Tiribelli, Olufunto O. Badmus, Terry D. Hinds
  Kidney360.2022; 3(5): 945.     CrossRef
• Effect of 2 years of calorie restriction on liver biomarkers: results from the CALERIE phase 2 randomized controlled trial
  James L. Dorling, Eric Ravussin, Leanne M. Redman, Manju Bhapkar, Kim M. Huffman, Susan B. Racette, Sai K. Das, John W. Apolzan, William E. Kraus, Christoph Höchsmann, Corby K. Martin
  European Journal of Nutrition.2021; 60(3): 1633.     CrossRef
• Bilirubin as a metabolic hormone: the physiological relevance of low levels
  Justin F. Creeden, Darren M. Gordon, David E. Stec, Terry D. Hinds
  American Journal of Physiology-Endocrinology and Metabolism.2021; 320(2): E191.     CrossRef
• Association of Serum Bilirubin Level with Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study of 1672 Obese Children
  Cristina Bellarosa, Giorgio Bedogni, Annalisa Bianco, Sabrina Cicolini, Diana Caroli, Claudio Tiribelli, Alessandro Sartorio
  Journal of Clinical Medicine.2021; 10(13): 2812.     CrossRef
• Crosstalk Between Plasma Cytokines, Inflammation, and Liver Damage as a New Strategy to Monitoring NAFLD Progression
  Tereza C. M. Fontes-Cal, Rafael T. Mattos, Nayara I. Medeiros, Bruna F. Pinto, Mayara Belchior-Bezerra, Bruna Roque-Souza, Walderez O. Dutra, Teresa C. A. Ferrari, Paula V. T. Vidigal, Luciana C. Faria, Cláudia A. Couto, Juliana A. S. Gomes
  Frontiers in Immunology.2021;[Epub]     CrossRef
• Is a Four-Week Ketogenic Diet an Effective Nutritional Strategy in CrossFit-Trained Female and Male Athletes?
  Krzysztof Durkalec-Michalski, Paulina M. Nowaczyk, Natalia Główka, Anna Ziobrowska, Tomasz Podgórski
  Nutrients.2021; 13(3): 864.     CrossRef
• Oxidative Stress and Related Biomarkers in Gilbert’s Syndrome: A Secondary Analysis of Two Case-Control Studies
  Karl-Heinz Wagner, Nazlisadat Seyed Khoei, Claudia Hana, Daniel Doberer, Rodrig Marculescu, Andrew Bulmer, Marlies Hörmann-Wallner, Christine Mölzer
  Antioxidants.2021; 10(9): 1474.     CrossRef
• Bilirubin deficiency renders mice susceptible to hepatic steatosis in the absence of insulin resistance
  Weiyu Chen, Sergey Tumanov, Daniel J. Fazakerley, James Cantley, David E. James, Louise L. Dunn, Taqi Shaik, Cacang Suarna, Roland Stocker
  Redox Biology.2021; 47: 102152.     CrossRef
• Biliverdin reductase as a target in drug research and development: Facts and hypotheses
  Cesare Mancuso
  Free Radical Biology and Medicine.2021; 172: 521.     CrossRef
• Association of Serum Bilirubin and Functional Variants of Heme Oxygenase 1 and Bilirubin UDP-Glucuronosyl Transferase Genes in Czech Adult Patients with Non-Alcoholic Fatty Liver Disease
  Jaromír Petrtýl, Karel Dvořák, Jan Stříteský, Martin Leníček, Alena Jirásková, Václav Šmíd, Martin Haluzík, Radan Brůha, Libor Vítek
  Antioxidants.2021; 10(12): 2000.     CrossRef
• Circulating chemerin level is associated with metabolic, biochemical and haematological parameters—A population‐based study
  Hsin‐Hua Chou, Ming‐Sheng Teng, Lung‐An Hsu, Leay‐Kiaw Er, Semon Wu, Yu‐Lin Ko
  Clinical Endocrinology.2021; 94(6): 927.     CrossRef
• The effects of Ramadan intermittent fasting on liver function in healthy adults: A systematic review, meta-analysis, and meta-regression
  MoezAlIslam Faris, Haitham Jahrami, Dana Abdelrahim, Nicola Bragazzi, Ahmed BaHammam
  Diabetes Research and Clinical Practice.2021; 178: 108951.     CrossRef
• The Protective Role of the Heme Catabolic Pathway in Hepatic Disorders
  Libor Vítek
  Antioxidants & Redox Signaling.2021; 35(9): 734.     CrossRef
• Circulating total bilirubin and risk of non-alcoholic fatty liver disease in the PREVEND study: observational findings and a Mendelian randomization study
  Setor K. Kunutsor, Monika Frysz, Niek Verweij, Lyanne M. Kieneker, Stephan J. L. Bakker, Robin P. F. Dullaart
  European Journal of Epidemiology.2020; 35(2): 123.     CrossRef
• Heme-Derived Metabolic Signals Dictate Immune Responses
  Giacomo Canesin, Seyed M. Hejazi, Kenneth D. Swanson, Barbara Wegiel
  Frontiers in Immunology.2020;[Epub]     CrossRef
• Renal resistive index in non-alcoholic fatty liver disease as an indicator of early renal affection
  Hossam El-Din A. Mahmoud, Wael A. Yousry, Shereen A. Saleh, Mohamed El Badry, Ahmed Hussein, Mostafa Hassan Ali, Hazem M. El-Hariri
  Egyptian Liver Journal.2020;[Epub]     CrossRef
• Plasma Krebs Cycle Intermediates in Nonalcoholic Fatty Liver Disease
  Yana Sandlers, Rohan R. Shah, Ryan W. Pearce, Jaividhya Dasarathy, Arthur J. McCullough, Srinivasan Dasarathy
  Journal of Clinical Medicine.2020; 9(2): 314.     CrossRef
• Physiological changes in the albumin-bound non-esterified free fatty acids critically influence heme/bilirubin binding properties of the protein: A comparative, in vitro, spectroscopic study using the endogenous biomolecules
  Mahtab Amoorahim, Mohammad Reza Ashrafi-Kooshk, Sajjad Esmaeili, Mohsen Shahlaei, Sajad Moradi, Reza Khodarahmi
  Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy.2020; 235: 118298.     CrossRef
• Long-term profile of serological biomarkers, hepatic inflammation, and fibrosis in a mouse model of non-alcoholic fatty liver disease
  Riki Toita, Jeong-Hun Kang
  Toxicology Letters.2020; 332: 1.     CrossRef
• Bilirubin remodels murine white adipose tissue by reshaping mitochondrial activity and the coregulator profile of peroxisome proliferator–activated receptor α
  Darren M. Gordon, Kari L. Neifer, Abdul-Rizaq Ali Hamoud, Charles F. Hawk, Andrea L. Nestor-Kalinoski, Scott A. Miruzzi, Michael P. Morran, Samuel O. Adeosun, Jeffrey G. Sarver, Paul W. Erhardt, Robert E. McCullumsmith, David E. Stec, Terry D. Hinds
  Journal of Biological Chemistry.2020; 295(29): 9804.     CrossRef
• Therapeutic application and construction of bilirubin incorporated nanoparticles
  Qing Yao, Ruijie Chen, Vadivel Ganapathy, Longfa Kou
  Journal of Controlled Release.2020; 328: 407.     CrossRef
• Rats Genetically Selected for High Aerobic Exercise Capacity Have Elevated Plasma Bilirubin by Upregulation of Hepatic Biliverdin Reductase-A (BVRA) and Suppression of UGT1A1
  Terry D. Hinds, Justin F. Creeden, Darren M. Gordon, Adam C. Spegele, Steven L. Britton, Lauren G. Koch, David E. Stec
  Antioxidants.2020; 9(9): 889.     CrossRef
• A Nomogram Model Based on Noninvasive Bioindicators to Predict 3‐Year Risk of Nonalcoholic Fatty Liver in Nonobese Mainland Chinese: A Prospective Cohort Study
  Xintian Cai, Xiayire Aierken, Ayguzal Ahmat, Yuanyuan Cao, Qing Zhu, Ting Wu, Nanfang Li, Marcello Maida
  BioMed Research International.2020;[Epub]     CrossRef
• Reduced Biliverdin Reductase-A Expression in Visceral Adipose Tissue is Associated with Adipocyte Dysfunction and NAFLD in Human Obesity
  Valentina Ceccarelli, Ilaria Barchetta, Flavia Agata Cimini, Laura Bertoccini, Caterina Chiappetta, Danila Capoccia, Raffaella Carletti, Claudio Di Cristofano, Gianfranco Silecchia, Mario Fontana, Frida Leonetti, Andrea Lenzi, Marco Giorgio Baroni, Eugeni
  International Journal of Molecular Sciences.2020; 21(23): 9091.     CrossRef
• Natural Product Heme Oxygenase Inducers as Treatment for Nonalcoholic Fatty Liver Disease
  David E. Stec, Terry D. Hinds
  International Journal of Molecular Sciences.2020; 21(24): 9493.     CrossRef
• Bilirubin Nanoparticles Reduce Diet-Induced Hepatic Steatosis, Improve Fat Utilization, and Increase Plasma β-Hydroxybutyrate
  Terry D. Hinds, Justin F. Creeden, Darren M. Gordon, Donald F. Stec, Matthew C. Donald, David E. Stec
  Frontiers in Pharmacology.2020;[Epub]     CrossRef
• Serum lactate levels are associated with serum alanine aminotransferase and total bilirubin levels in patients with type 2 diabetes mellitus: A cross-sectional study
  Minori Ishitobi, Toshio Hosaka, Naru Morita, Ken Kondo, Toshitaka Murashima, Atsuko Kitahara, Kazuto Takahashi, Yoshikazu Sumitani, Toshiaki Tanaka, Toshihiko Yokoyama, Takuma Kondo, Hitoshi Ishida
  Diabetes Research and Clinical Practice.2019; 149: 1.     CrossRef
• Reduced biliverdin reductase-A levels are associated with early alterations of insulin signaling in obesity
  Flavia Agata Cimini, Andrea Arena, Ilaria Barchetta, Antonella Tramutola, Valentina Ceccarelli, Chiara Lanzillotta, Mario Fontana, Laura Bertoccini, Frida Leonetti, Danila Capoccia, Gianfranco Silecchia, Claudio Di Cristofano, Caterina Chiappetta, Fabio D
  Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2019; 1865(6): 1490.     CrossRef
• Western Diet-Induced Metabolic Alterations Affect Circulating Markers of Liver Function before the Development of Steatosis
  Daniela Gabbia, Marco Roverso, Maria Guido, Diana Sacchi, Michela Scaffidi, Maria Carrara, Genny Orso, Francesco Paolo Russo, Annarosa Floreani, Sara Bogialli, Sara De Martin
  Nutrients.2019; 11(7): 1602.     CrossRef
• CRISPR Cas9-mediated deletion of biliverdin reductase A (BVRA) in mouse liver cells induces oxidative stress and lipid accumulation
  Darren M. Gordon, Samuel O. Adeosun, Somtochukwu I. Ngwudike, Christopher D. Anderson, John E. Hall, Terry D. Hinds, David E. Stec
  Archives of Biochemistry and Biophysics.2019; 672: 108072.     CrossRef
• Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date
  Somaya Albhaisi, Arun J. Sanyal
  Pharmaceutical Medicine.2019; 33(6): 451.     CrossRef
• Hepatoprotective Effects of a Ruthenium(II) Schiff Base Complex in Rats with Diet-Induced Prediabetes
  Lindokuhle Patience Mabuza, Mlindeli Wilkinson Gamede, Sanam Maikoo, Irvin Noel Booysen, Phikelelani Siphosethu Nguban, Andile Khathi
  Current Therapeutic Research.2019; 91: 66.     CrossRef
• Systemic regulation of bilirubin homeostasis
  Ryoichi Fujiwara, Mathias Haag, Elke Schaeffeler, Anne T. Nies, Ulrich M. Zanger, Matthias Schwab
  Hepatology.2018; 67(4): 1609.     CrossRef
• Bilirubin in the Liver–Gut Signaling Axis
  Abdul-Rizaq Hamoud, Lauren Weaver, David E. Stec, Terry D. Hinds
  Trends in Endocrinology & Metabolism.2018; 29(3): 140.     CrossRef
• Biliverdin reductase and bilirubin in hepatic disease
  Lauren Weaver, Abdul-rizaq Hamoud, David E. Stec, Terry D. Hinds
  American Journal of Physiology-Gastrointestinal and Liver Physiology.2018; 314(6): G668.     CrossRef
• Bilirubin, a new therapeutic for kidney transplant?
  Vikram L. Sundararaghavan, Sivjot Binepal, David E. Stec, Puneet Sindhwani, Terry D. Hinds
  Transplantation Reviews.2018; 32(4): 234.     CrossRef
• Loss of biliverdin reductase-A promotes lipid accumulation and lipotoxicity in mouse proximal tubule cells
  Samuel O. Adeosun, Darren M. Gordon, Mary Frances Weeks, Kyle H. Moore, John E. Hall, Terry D. Hinds, David E. Stec
  American Journal of Physiology-Renal Physiology.2018; 315(2): F323.     CrossRef
• Genetically Regulated Bilirubin and Risk of Non-alcoholic Fatty Liver Disease: A Mendelian Randomization Study
  Lei Luo, Ping An, Xinyong Jia, Xiaobian Yue, Sujun Zheng, Shuang Liu, Yu Chen, Wei An, Cheryl A. Winkler, Zhongping Duan
  Frontiers in Genetics.2018;[Epub]     CrossRef
• Relationship between serum bilirubin concentrations and diabetic nephropathy in Shanghai Han’s patients with type 1 diabetes mellitus
  Xu Li, Lei Zhang, Haibing Chen, Kaifeng Guo, Haoyong Yu, Jian Zhou, Ming Li, Qing Li, Lianxi Li, Jun Yin, Fang Liu, Yuqian Bao, Junfeng Han, Weiping Jia
  BMC Nephrology.2017;[Epub]     CrossRef
• Mice with hyperbilirubinemia due to Gilbert’s syndrome polymorphism are resistant to hepatic steatosis by decreased serine 73 phosphorylation of PPARα
  Terry D. Hinds, Peter A. Hosick, Shujuan Chen, Robert H. Tukey, Michael W. Hankins, Andrea Nestor-Kalinoski, David E. Stec
  American Journal of Physiology-Endocrinology and Metabolism.2017; 312(4): E244.     CrossRef
• Does bilirubin protect against developing diabetes mellitus?
  Lars H. Breimer, Dimitri P. Mikhailidis
  Journal of Diabetes and its Complications.2016; 30(4): 728.     CrossRef
• Association between bilirubin and risk of Non-Alcoholic Fatty Liver Disease based on a prospective cohort study
  Jianbo Tian, Rong Zhong, Cheng Liu, Yuhan Tang, Jing Gong, Jiang Chang, Jiao Lou, Juntao Ke, Jiaoyuan Li, Yi Zhang, Yang Yang, Ying Zhu, Yajie Gong, Yanyan Xu, Peiyi Liu, Xiao Yu, Lin Xiao, Min Du, Ling Yang, Jing Yuan, Youjie Wang, Weihong Chen, Sheng We
  Scientific Reports.2016;[Epub]     CrossRef
• Does bilirubin prevent hepatic steatosis through activation of the PPARα nuclear receptor?
  Terry D. Hinds, Samuel O. Adeosun, Abdulhadi A. Alamodi, David E. Stec
  Medical Hypotheses.2016; 95: 54.     CrossRef
• Bilirubin Binding to PPARα Inhibits Lipid Accumulation
  David E. Stec, Kezia John, Christopher J. Trabbic, Amarjit Luniwal, Michael W. Hankins, Justin Baum, Terry D. Hinds, Hervé Guillou
  PLOS ONE.2016; 11(4): e0153427.     CrossRef
• Total Bilirubin Levels Predict Subclinical Atherosclerosis in Patients With Prediabetes
  Hikmet Hamur, Hakan Duman, Levent Demirtas, Eftal Murat Bakirci, Murtaza Emre Durakoglugil, Husnu Degirmenci, Kamuran Kalkan, Erkan Yildirim, Ertan Vuruskan
  Angiology.2016; 67(10): 909.     CrossRef
• Biliverdin Reductase A Attenuates Hepatic Steatosis by Inhibition of Glycogen Synthase Kinase (GSK) 3β Phosphorylation of Serine 73 of Peroxisome Proliferator-activated Receptor (PPAR) α
  Terry D. Hinds, Katherine A. Burns, Peter A. Hosick, Lucien McBeth, Andrea Nestor-Kalinoski, Heather A. Drummond, Abdulhadi A. AlAmodi, Michael W. Hankins, John P. Vanden Heuvel, David E. Stec
  Journal of Biological Chemistry.2016; 291(48): 25179.     CrossRef
• Role of physical activity in nonalcoholic fatty liver disease in terms of visceral obesity and insulin resistance
  Min‐Sun Kwak, Donghee Kim, Goh Eun Chung, Won Kim, Yoon Jun Kim, Jung‐Hwan Yoon
  Liver International.2015; 35(3): 944.     CrossRef
• Looking to the horizon: the role of bilirubin in the development and prevention of age-related chronic diseases
  Karl-Heinz Wagner, Marlies Wallner, Christine Mölzer, Silvia Gazzin, Andrew Cameron Bulmer, Claudio Tiribelli, Libor Vitek
  Clinical Science.2015; 129(1): 1.     CrossRef
• Nonalcoholic Steatohepatitis Associated With Metabolic Syndrome
  Kyong Yeun Jung, Sun Young Cho, Hyung Joon Kim, Suk Bae Kim, Il Han Song
  Journal of Clinical Gastroenterology.2014; 48(10): 883.     CrossRef
• Low serum bilirubin concentration is a novel risk factor for the development of albuminuria in patients with type 2 diabetes
  Hiroshi Okada, Michiaki Fukui, Muhei Tanaka, Shinobu Matsumoto, Kanae Kobayashi, Hiroya Iwase, Kiichiro Tomiyasu, Koji Nakano, Goji Hasegawa, Naoto Nakamura
  Metabolism.2014; 63(3): 409.     CrossRef
• The association between indirect bilirubin levels and liver fibrosis due to chronic hepatitis C virus infection
  Mustafa Cengiz, Guldal Yılmaz, Seren Ozenirler
  Pathology - Research and Practice.2014; 210(8): 488.     CrossRef
• Effect of Low Serum Total Bilirubin Levels (≤0.32 mg/dl) on Risk of Coronary Artery Disease in Patients With Metabolic Syndrome
  Young Shin Song, Bo Kyung Koo, Nam H. Cho, Min Kyong Moon
  The American Journal of Cardiology.2014; 114(11): 1695.     CrossRef
• Systematic review: Association of serum bilirubin and non-alcoholic fatty liver disease: A feasible therapeutic avenue?
  Mohamed S Anwar
  World Journal of Pharmacology.2014; 3(4): 209.     CrossRef
• Non‐alcoholic fatty liver disease: Factors associated with its presence and onset
  Teruki Miyake, Teru Kumagi, Shinya Furukawa, Yoshio Tokumoto, Masashi Hirooka, Masanori Abe, Yoichi Hiasa, Bunzo Matsuura, Morikazu Onji
  Journal of Gastroenterology and Hepatology.2013; 28(S4): 71.     CrossRef